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ABSTRACT 
Cancer is the second leading cause of death in the United States. Due to the increase in 
exposure to cancer-causing environmental factors, the presence of chronic conditions, 
and the increase in age-related mutations in normal tissue, cancer incidence is 
positively correlated with age. Because of the increase in life expectancy due to 
advances in medicine, the frequency of cancer incidence is expected to rise in the 
future. For these reasons, devising methods to efficiently diagnose and treat cancer is 
extremely important. 
 
Effective targeting of cancer cells within tumors would allow for improvement in the 
efficacy of treatment and the reduction of side effects. Tumor targeting falls into three 
broad categories: passive targeting, active targeting, and physical targeting. Passive 
targeting generally employs the enhanced permeability and retention effect, a 
phenomenon that leads to the localization of a certain range of sizes of 
macromolecules in tumor tissue due to the non-intact vasculature present in this tissue. 
Passive targeting can work well to deliver some therapeutic agents to solid tumors, but 
lacks targeting specificity and can therefore result in substantial targeting of healthy 
tissue, especially the liver, lymph nodes, and spleen. 
 
Active targeting relies on a much greater presence of certain characteristics, called 
biomarkers, on or in cancer cells than on/in normal cells. To exploit active targeting, 
therapeutic agents are conjugated to targeting moieties like antibodies, aptamers, or 
small molecules that have a high affinity to these biomarkers. Active targeting has 
some advantages over passive targeting, namely, higher targeting specificity. 
However, one significant disadvantage of active targeting is its reliance on the 
overexpression of biomarkers in cancer cells: tumor tissue is very heterogeneous, with 
varying levels of expression across the cancer cell population; additionally, these 
biomarkers are usually present in normal tissue, leading to the undesirable targeting of 
healthy tissue. 
 
Physical targeting relies on a difference in physical properties, such as temperature, 
oxygenation, or pH, between normal tissue and cancer tissue. These physical 
characteristics can be more universal to tumor tissue, regardless of the tissue 
vasculature or biomarker expression. Physical targeting offers specificity advantages 
over passive targeting, and offers advantages over active targeting based on the 
universality and specificity of the targeted physical traits, compared to the broader, 
varying levels of expression of active-targeted biomarkers. 
 
It has been known for over fifty years that tumor tissue undergoes acidification due to 
a switch in metabolic pathway resulting in the production of high levels of lactic acid 
and protons, a phenomenon known as the Warburg effect. In addition, cancer cells 
overexpress certain membrane proteins that catalyze reactions in the blood that result 
in further acidification. Although cell surface acidity is a feature that is ubiquitous to 
solid tumors, as a biomarker it has been greatly overlooked in favor of expressed traits 
like growth factors, protein receptors, and antigens. 
 
pH Low Insertion Peptides (pHLIPs) comprise a family of pH-sensitive peptides, and 
sense and target the acidity present at the surface of cancer cells. pHLIPs can be 
conjugated to many different types of imaging and therapeutic agents, and, targeting 
the physical characteristic of pH, are able to selectively deliver these agents to tumor 
tissue while avoiding normal tissue. The mechanism of action of pHLIP is based on 
membrane-associated folding triggered by low pH: at low pH, a high concentration of 
protons results in the protonation of certain residues in pHLIP which leads to an 
increase in peptide hydrophobicity and drives the peptide to partition into the 
hydrophobic core of the membrane; here, pHLIP folds into a transmembrane helix, 
leaving one terminus in the extracellular space while the other terminus is translocated 
across the cell membrane into the cytoplasm. 
 
The main goal of this work was to optimize various pHLIPs and to evaluate the utility 
of pHLIP conjugates in the selective delivery of imaging and therapeutic agents used 
in specific medical applications: namely, for PET imaging and for the intracellular 
delivery of toxic cargo. Over the course of this work, we introduced several new 
imaging and drug-delivery conjugates based on existing pHLIP variants, as well as 
several new drug-delivery conjugates based on novel pHLIP variants. An emphasis 
was placed on the biophysical characterization of new peptides and conjugates, and 
the measurement of the ability of drug-laden conjugates to induce cell death in in vitro 
assays in a pH-dependent manner. Aside from these points upon which we place 
special emphasis, the effects of physiological levels of free divalent cations on protein 
folding were investigated via biophysical measurements for the first time. 
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PREFACE 
This dissertation is written in “Manuscript” format, using the Thesis/Dissertation 
template of the University of Rhode Island. There are three manuscripts included in 
this dissertation, each of which comprises a chapter. The tables and figures of each 
manuscript are listed under the corresponding chapter in the list of tables and figures. 
 
The results of our studies presented in the first two chapters were published in the 
following papers: 
1. Wyatt LC, Lewis JS, Andreev OA, Reshetnyak YK, Engelman DM. 
“Applications of pHLIP Technology for Cancer Imaging and Therapy.” (2017) 
Trends in Biotechnology. 35(7)653-664. 
2. Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta M, Pourat J, 
Longo VA, Carlin SD, Engelman DM, Andreev OA, Reshetnyak YK, Viola-
Villegas N, Lewis JS. (2016) “PET imaging of extracellular pH in tumors with 
64
Cu- and 
18
F-labeled pHLIP peptides: A structure-activity optimization 
study.” Bioconjugate Chemistry 27(9):2014-2023. 
 
The final chapter is composed of research that has been submitted for publication: 
3. Wyatt LC, Moshnikova A, Crawford T, Engelman DM, Andreev OA, 
Reshetnyak YK. “New pHLIPs for the Targeted Intracellular Delivery of 
Cargo Molecules to Tumors.” Manuscript submitted for publication. 
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ABSTRACT  
Acidity is a biomarker of cancer that is not subject to the blunting effects of clonal 
selection, effects that reduce the efficacy of other biomarker technologies, like 
antibody targeting. The pH (Low) Insertion Peptides (pHLIPs) provide new 
opportunities for targeting acidic tissues. Through the physical mechanism of 
membrane-associated folding, pHLIPs are triggered by the acidic microenvironment to 
insert and span the membranes of tumor cells. The pHLIP platform can be applied to 
imaging acidic tissues, delivering cell-permeable and impermeable molecules to the 
cytoplasm, and promoting the cellular uptake of nanoparticles. Since acidosis is a 
hallmark of tumor development, progression, and aggressiveness, the pHLIP 
technology may prove useful in targeting cancer cells and metastases for tumor 
diagnosis, imaging, and therapy. 
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EXTRACELLULAR ACIDITY  
Acidity is a hallmark and predictor of tumor development and progression 
Even in the presence of oxygen, cancer cells use the anaerobic pathway more 
than normal cells do, a phenomenon known as the Warburg effect [1-3]. Normally, 
cell metabolism occurs through a low rate of glycolysis followed by oxidation of 
pyruvate in the mitochondria, whereas anaerobic metabolism is associated with a high 
rate of glycolysis and lactic acid fermentation [4]. Protons are a byproduct of both 
pathways; however, when cells use glycolysis and lactic acid fermentation at a high 
rate, excess lactate and protons are produced. In order to maintain homeostasis, a cell 
must keep its intracellular pH at the physiological level, around pH 7.2-7.4. If the pH 
inside the cell drops, the cell will pump excess acidity into the extracellular space to 
maintain physiological pH levels in the cytoplasm. Additionally, cancer cells 
overexpress surface carbonic anhydrases (CAIX and CAXII), which catalyze the 
transformation of carbon dioxide and water into carbonic acid (bicarbonate and 
protons) [5-7]. Thus, excessive amounts of acid and protons accumulate in the 
extracellular space, especially in poorly perfused tumor regions, reducing the pH of 
the extracellular space and leading to tumor acidification [8, 9]. 
Not only is acidity a hallmark of tumor development, but acidity also facilitates 
tumor growth [10]. The acidification of the healthy tissue surrounding a tumor leads to 
tissue remodeling that allows for local invasion. Studies in which the pH of the surface 
of tumors was monitored showed that the regions of the highest tumor invasion (see 
Glossary) corresponded to areas of highest acidity [10]. Therefore, targeting the most 
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acidic regions of tumors is especially beneficial because the most acidic regions are 
the most aggressive [11]. 
 
Bulk extracellular pH versus cancer cell surface pH 
Recent studies using a fluorophore with a pH-dependent emission spectrum 
have shown that the pH in the vicinity of the plasma membrane of cancer cells is about 
0.3-0.7 pH units lower than the bulk extracellular pH [12]. In experiments in vitro, 
where the pH of the solution in which the cancer cells are growing (bulk pH) is 
maintained at pH 7.4, the cell surface pH for highly metastatic cells has been shown to 
be around pH 6.7. In three-dimensional tumor models, ex vivo mouse tumor tissue, and 
live animals, the cancer cell surface pH has been shown to be as low as pH 6.0. Thus, 
cancer cells have a “crown of acidity” near their cell surfaces. The pH becomes less 
acidic with distance from the cell surface and, therefore, the bulk extracellular pH can 
be relatively high, especially in well-perfused regions. However, the cell surface pH 
always remains low (acidic). The bulk extracellular pH correlates with perfusion, 
while the cell surface pH is expected to be less dependent on tumor tissue perfusion, 
and to be a predictive marker of tumor development and progression, since more 
aggressive tumor cells are more acidic. 
 
pHLIP TECHNOLOGY 
Peptides of the pHLIP family and their mechanism of action 
 The pH (Low) Insertion Peptide (pHLIP®, see Glossary) was derived from the 
C-helix of the protein bacteriorhodopsin, and originally was called the BRC peptide 
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[13]. The salient feature of a pHLIP is its ability to sense the pH in the vicinity of the 
plasma membrane and to spontaneously form a helix and insert across the membrane 
when the extracellular environment is acidic (Figure 1) [14, 15]. Numerous 
modifications have been made to the primary sequence of pHLIPs to evaluate and tune 
the properties of the interaction of the pHLIP with the cell membrane [16]. These 
modifications include testing a pHLIP consisting entirely of D-amino acids against 
one containing entirely L-amino acids (no change was observed) [17]; truncating and 
reversing the wild-type (WT) pHLIP sequence, and in so doing introducing new 
pHLIP variants [18, 19]; swapping some or all aspartic acid residues for glutamic acid 
residues [16, 20, 21], positively-charged lysine residues [18, 22-30], or the 
protonatable non-standard amino acids such as γ-carboxyglutamic acid and α-
aminoadipic acid [31]; and the de novo design of a pHLIP variant [32]. 
Variation of the WT pHLIP sequence led to novel pHLIPs, such as Variant 3 
(Var3), with significantly improved tumor targeting properties [18, 28, 33-35]. The 
overall features of the pHLIP peptide sequences are still present in all variants: a 
middle region interspersed with a combination of hydrophobic residues and residues 
that are negatively charged at physiological pH but become neutrally charged at low 
pH, and hydrophilic flanking regions, with the membrane-inserting C-terminus (in 
most sequences) containing a few additional protonatable residues (Box 1) [9, 36-38]. 
Var3, in particular, has a truncated membrane-inserting end, which leads to its faster 
partitioning into the cell membrane to form a transmembrane helix. This variant 
exhibits the highest difference between the Gibbs free energies of its interaction with 
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the membrane at low and high pHs, which ensures pH-dependent preferential targeting 
of the cancer cells [18]. 
The mechanism of action of all peptides in the pHLIP family is well 
understood: membrane-associated folding is triggered by the protonation and increase 
in hydrophobicity of the peptide when exposed to acidic environments (Figure 2) [15, 
19, 22, 39, 40]. At physiological pH, a population of pHLIPs mainly exists as an 
equilibrium between two states: a solvated state in which the pHLIP adopts a 
conformation with little secondary structure, and a state in which the pHLIP remains 
disordered and is adsorbed to the surface of the cell membrane [15]. At low pH, an 
increased concentration of protons results in the protonation of negatively charged 
residues at key locations in the peptide. This protonation increases the overall 
hydrophobicity of the pHLIP, resulting in its folding to form a helix that partitions 
across the bilayer as a transmembrane helix. The inserted peptide leaves its N-
terminus in the extracellular space while the C-terminus is translocated across the 
membrane into the cytoplasm. The lipid composition of the cell membrane can 
contribute to modulation of the binding and insertion into the membrane of a pHLIP 
[20, 41, 42]. 
It is important to distinguish between the pHLIP family, which consists of 
membrane-inserting peptides, and cell-penetrating peptides (CPPs) or amphipathic 
pore-forming peptides. CPPs and pore-forming peptides have entirely different 
mechanisms of action and different biological performance; they are not part of the 
pHLIP family. 
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Targeting extracellular acidity 
Targeting cancer cells by exploiting extracellular acidification should be 
compared with other targeting approaches, which are commonly based on the presence 
of growth factors or tumor antigens. A problem in targeting these kinds of specific 
features is that the cancer cell population, both between tumors and within an 
individual tumor, is extremely heterogeneous and very adaptable [43]. The potential 
for successfully treating tumors that do not express or exhibit limited expression of the 
targeted growth factor or antigen is low, and, even in treatment-responsive tumors, 
minority populations of cancer cells can undergo clonal selection and eventually re-
grow into a treatment-resistant phenotype. Subsequent treatments will either have 
limited efficacy or be entirely ineffective. Additionally, these types of targeting 
methods have the potential to severely damage healthy tissues where the growth factor 
or antigen might also be present. Therefore, targeting tumor acidity, a physical 
characteristic that is not only found across an entire tumor but is found in tumors of all 
sizes, including metastases, could have advantages over targeting methods based on 
characteristics that are found only in some tumors or some cancer cell populations [44, 
45]. 
Acidity is produced not only by cancerous tissue, but also by any tissue that is 
experiencing hypoxia: the lack of oxygen in the tissue triggers cells to switch to a high 
rate of the anaerobic, glycolytic energy production pathway, consequently resulting in 
acidification. pHLIPs have been shown to target infections in lungs [46], inflammatory 
arthritis [22], and ischemic myocardium, a consequence of heart disease, and could be 
used for diagnosis and treatment thereof [26]. It is also possible that pHLIPs could be 
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used as targeted treatment in ischemic strokes. In contrast to diseased tissue, healthy 
tissue is typically not associated with increased acidity except in the gastrointestinal 
tract and kidney, the pHs of which might be regulated by the implementation of a 
special diet or supplementary drinks if their acidity proves problematic.  
 In contrast to other pH-sensitive agents that sense bulk pH, members of the 
pHLIP family of peptides bind to cell surfaces at all pH values and therefore sense pH 
at the surfaces of cancer cells, where pH is the lowest, further accentuating the pH 
sensitivity of the peptides. The pH-dependent behavior and inserted conformation of 
pHLIPs make them useful for delivering cargo inside cancer cells (by attaching the 
cargo to the inserting end of the peptides) or for tethering cargo to the cell membrane 
(by conjugating to the non-inserting end of the peptides) [9]. Additionally, small-angle 
X-ray scattering experiments have shown that pHLIPs do not form oligomers larger 
than tetramers, even at very high concentrations [47], a useful property for drugs to be 
used intravenously, as the local concentration at the injection site is generally much 
higher than the drug concentration when it reaches the target area, and it is crucial that 
the drug does not aggregate upon injection. These basic features give rise to a wide 
variety of possible applications in diagnostic imaging, fluorescence guided surgery, 
the intracellular delivery of small molecules like toxins and gene regulation agents, the 
delivery of proteins to the surfaces of cells, and the delivery and uptake enhancement 
of nanoparticles. 
 
APPLICATIONS OF pHLIP TECHNOLOGY 
Diagnostic nuclear imaging 
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Positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT) are imaging techniques that rely on the delivery of radioactive 
imaging agents to targeted tissue. One of the main challenges in PET/SPECT imaging 
is to obtain images of target tissue that contrast highly with the image background, 
motivating the use of a targeting agent. When a radionuclide is conjugated to the non-
inserting terminus of a pHLIP (Figure 3A), the resulting construct not only targets 
tumor tissue very well, but also remains securely in the tumor long enough to allow 
the excess, non-inserted construct to clear from normal tissues, resulting in higher 
contrast images [17, 23, 25, 29, 33]. Success has been seen using the radioisotopes 
18
F 
(9 ± 2 %ID/g at 4 h p.i.) and 
64
Cu (19 ± 2%ID/g at 24 h p.i.) conjugated to Var3 [33]. 
These constructs are in the process of clinical translation as novel nuclear imaging 
markers of diseased tissue acidity. 
  
Fluorescence-guided surgery and ex vivo imaging 
Fluorescence-guided surgery utilizing pHLIP technology could ease the 
challenges of tumor resection, such as visualization of all cancerous lesions, including 
flat lesions, ultimately reducing the number of surgeries that result in positive 
margins. These features could improve surgery outcomes and reduce tumor 
recurrences. Excellent targeting and labeling by different fluorescent pHLIPs of 
primary tumors and sub-millimeter-sized metastatic lesions has been demonstrated on 
various tumor models, including transgenic breast, prostate, melanoma and pancreatic 
mice models [11, 24, 28, 34, 35, 48]. 
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Excellent staining and visualization of urothelial tumors has been observed in 
excised human bladders using an ICG pHLIP imaging agent [48]. This imaging agent 
marked high-grade urothelial carcinomas, both muscle-invasive and non-muscle-
invasive lesions, and, most importantly, flat lesions, which are the most difficult to 
identify and commonly necessitate further surgery. Carcinoma in situ was accurately 
diagnosed in eleven cases, whereas only four cases were identified using white light. 
The sensitivity and specificity of targeting by the ICG pHLIP imaging agent were 
found to be 97% and 100%, respectively, excluding staining of necrotic and 
previously treated tissue.  
Another application of fluorophore-labeled pHLIPs is the ex vivo staining and 
imaging of biopsy samples or tissue after surgical resections. Fluorophore-conjugated 
pHLIPs have shown utility in accurately identifying head and neck cancer, proving 
their potential to be useful tools for the early identification and evaluation of dysplasia 
and neoplasia [49, 50]. In these studies, both the normal and suspect biopsy samples 
were stained ex vivo with Alexa Fluor647 pHLIP. Imaging was performed before and 
after staining, and the ratio of intensity increase of suspect tissue to normal tissue was 
calculated; a two- to six-fold increase in fluorescence intensity ratio was observed in 
cancerous tissue compared to normal tissue (with no ratio increase for the inflamed 
tissue). 
The conjugation of the pH-sensing fluorescent dye SNARF to a pHLIP results 
in a compound that can measure pH at the surface of individual cells, which differs 
greatly from the more easily and commonly measured bulk pH [12]. Currently, 
approaches for cell surface pH mapping using SNARF-pHLIP in liquid and solid 
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biopsy samples are being developed, which might result in an opportunity to get 
information about the metabolic status of tumors, ultimately aiding in the prediction of 
tumor aggressiveness and the tailoring of therapy. SNARF-pHLIP might also be used 
in longitudinal studies as a very useful tool in the investigation of the development and 
progression of diseases. 
 
Intracellular delivery of drug-like and polar therapeutic cargo molecules 
 pHLIPs translocate their C-termini into the cytoplasms of tumor cells, allowing 
the intracellular delivery of therapeutic cargo molecules to treat primary tumor tissue 
as well as metastases. The ability of pHLIPs to target metastases is especially 
important: in cancer cases, the primary tumor is generally not the reason for poor 
prognoses; more often, it is tumor invasion, unseen by traditional diagnostic 
procedures, that proves fatal. 
Extensive biophysical investigations, including kinetics and thermodynamics 
studies, have been conducted to determine the activation energy required for the 
membrane insertion/folding (as well as unfolding/exit) of pHLIPs [19-21, 39, 51]. 
These studies set the foundation for the development of novel approaches in drug 
delivery that are based on employing the energy of membrane-associated folding and 
the kinetically controlled pH-triggered translocation of cargo molecules across the 
lipid bilayer of the cell membrane (Figure 3B). Cargoes can be linked to the C-
terminus, for example, by including a cysteine in the pHLIP sequence and attaching 
the cargo via a disulfide that is cleaved in the cytoplasm, releasing the cargo. 
Following fundamental studies, numerous in vitro and in vivo investigations have 
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demonstrated that pHLIPs can deliver several different payloads, such as fluorescent 
dyes, toxins, drugs, peptides, and peptide nucleic acids (PNAs) [14, 52-61]. The 
many molecules delivered into cells by pHLIPs can be conceptualized in two 
categories: drug-like, cell-permeable molecules; and polar, cell-impermeable cargoes. 
In the first case, pHLIPs might improve the pharmacokinetics and favorably alter the 
biodistribution of drugs, resulting in enhanced tumor accumulation. In the second 
case, pHLIPs, in addition to tumor targeting, can deliver polar molecules that cannot 
cross the plasma membrane via passive diffusion. 
Additionally, it is possible to tune the intracellular delivery of cargo by altering 
the C-terminal sequence, by choices of the linker connecting cargo to a pHLIP, and/or 
by attaching modulator molecules [52-54]. Changing the efficiency of cargo 
translocation leads to a change in biological response: systematic studies in which 
polar toxins are conjugated to pHLIPs via cleavable linkers of different 
hydrophobicity show subtle changes in the insertion properties of the constructs and, 
therefore, in the resulting cytotoxicity. Thus, depending on cargo polarity, the 
translocation of cargo across cellular membranes could be optimized by the proper 
selection of pHLIPs, linkers and modulator molecules. 
At low pH (pH <6.5), pHLIPs promote delivery of cell-permeable therapeutic 
cargoes such as the tubulin-binding toxin monomethyl auristatin E (MMAE) and the 
DNA intercalator doxorubicin, and reduces the cellular entry of these cargoes into 
healthy tissue at normal physiological pH [57, 58]. pHLIP MMAE conjugates have 
cytotoxic effects at low pH, inhibiting cell growth by more than 90% , and targeted 
triple-negative breast cancer tumors in mice [58]. 
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One of the most attractive therapeutic applications of pHLIPs is their ability to 
deliver polar molecules. Studies have been conducted using polar cyclic toxins from 
the death cap mushroom (Amanita phalloides): phalloidin, phallacidin and amanitin. 
Phalloidin and phallacidin bind to F-actin, while amanitin is an inhibitor of RNA 
polymerase II. All toxins, when conjugated to pHLIPs, have shown a pH-dependent 
ability to induce cell death [52, 53]. α-Amanitin is the most potent cargo studied so 
far, and, when conjugated to a pHLIP and exposed to cancer cells for less than two 
hours, it displayed a four- to five-fold higher antiproliferative effect at low pH (pH 
6.5) compared with physiological pH [54]. 
Also, pHLIPs have been proven to deliver peptides to interfere with the 
biological action of protein receptors or to disrupt mitochondrial cellular membranes 
[59, 60]. PAR1 is a protein receptor that is overexpressed in many cancer cells. A 
PAR1 protein fragment was shown to be translocated across the cell membrane by a 
pHLIP, where it interacted with the intracellular domain of the PAR1 receptor, 
rendering the protein receptor inactive and inducing pH-dependent cytotoxicity [59].  
 
Intracellular delivery of gene-regulation agents 
There is an expectation that future therapy (including cancer therapy) will be 
based on drugs that induce genetic interference in cancer cells. Efficiently modulating 
gene expression inside cancer cells and either reprogramming them to be normal cells 
or inducing apoptosis will be a significant breakthrough. Oncogenic microRNAs 
(oncomiRs) are miRNAs whose overexpression is associated with cancer 
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development; thus, it is desirable to inhibit an oncomiR, which can be achieved using 
complementary synthetic RNA strands, such as PNAs [56, 62, 63]. 
The main obstacle to the successful use of PNA antimiRs is that they do not 
cross cell membranes. pHLIPs, however, have been shown to deliver PNAs to cancer 
cells by virtue of their inherent targeting capability and folding energy. pHLIP-
mediated intracellular delivery of PNAs targeting the miR-155 oncomiR was 
shown in a mouse model of large B-cell lymphoma [56]. Treatment of 
lymphadenopathic miR-155 mice with pHLIP anti-oncomiR PNA leads to tumor 
burden reduction and prevention of lymphocyte metastases. 
 Another approach to gene therapy involves the intracellular delivery of 
plasmid DNAs (pDNAs). In one study, a pDNA expressing growth factor-interfering 
RNA was attached to a dendrimer via electrostatic interaction, and the dendrimer-
pDNA complex was conjugated to a pHLIP. The study showed higher cellular uptake 
at low pH compared to normal pH and resulted in an 86% inhibition of the targeted 
growth factor [64]. 
 
Targeting of therapeutic agents to cell surfaces 
 Another interesting use for pHLIPs is the delivery of therapeutic agents to the 
extracellular surfaces of cells, which might selectively activate various signaling 
pathways. An example of this principle is shown in the use of tissue factor (TF), a 
protein that anchors to the plasma membrane and induces blood coagulation. 
However, targeting is crucial for the successful use of tissue factor to accomplish 
thrombotic occlusion; otherwise, harmful side effects would be common. The tissue 
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factor protein naturally has a transmembrane domain that anchors it to cell surfaces. A 
study in which the transmembrane domain of the natural tissue factor was truncated 
and replaced with a pHLIP (resulting in tTF-pHLIP) showed targeting of the acidic 
tumor vasculature, and the tTF-pHLIP induced local blood coagulation. The 
administration of the tTF-pHLIP selectively induced thrombotic occlusion in tumor-
bearing mice, impairing tumor growth without any obvious side effects [65]. 
 
Nanotechnology 
 In the realm of nanotechnology, pHLIPs might find a variety of uses [66]. In 
nanotechnology applications, multiple pHLIPs decorate a single nanoparticle, which 
can range in size from a few nanometers to hundreds of nanometers, in contrast to the 
single peptide-cargo conjugates described above (Box 2). Nanocarriers decorated with 
pHLIPs are biocompatible, can target tumors, and demonstrate enhanced cellular 
uptake by cancer cells. Some pHLIP-coated nanoparticles that have been investigated 
are lipid, polymer, and metal-based nanomaterials [27, 67, 68]. 
In pHLIP-coated liposomes, pHLIPs promote lipid exchange and fusion 
between the lipid bilayer of the liposome and the cellular membrane [67]. Fusion with 
cellular or endosomal membranes allows the direct release of polar payloads into the 
cytoplasm, or the transfer of hydrophobic payloads into the membrane lipid bilayer 
(Figure 4) [67]. The principle of pHLIP-mediated liposomal fusion was used to 
deliver the hydrophobic peptide gramicidin A, a monovalent ion channel. Introducing 
pores into the targeted cell membrane disrupts ion balance, resulting in apoptosis [67]. 
This case demonstrates that pHLIPs might be used not only to improve liposome 
  
 
 
16 
targeting over passive targeting methods, but also to enhance payload delivery into 
cells by promoting the fusion of the liposome with the cell membrane. 
Gold nanoparticles have found various applications in medicine, including 
imaging, radiation therapy enhancement, and hyperthermia localization. The 
conjugation of pHLIP to gold nanoparticles has been shown to enhance cancer cell 
uptake by over 600% at low pH compared with cells treated with gold nanoparticles 
alone [27], and to promote the internalization of gold nanoparticles in human platelets 
[69]. Tumor targeting specificity was observed in studies of pHLIP-coated gold 
nanoclusters, ultimately resulting in the enhancement of radiation effects and 
increased cytotoxicity [70]. Additionally, pHLIP-coated hollow gold nanospheres 
(HAuNS) containing chlorin e6 (Ce6), a chemical used to amplify the response of 
tumor cells to photodynamic therapy, were developed. The HAuNS-pHLIP-Ce6, when 
irradiated with near-infrared light, treated tumors more effectively than hollow gold 
nanospheres alone because of the photosensitizer-enhanced hyperthermia due to Ce6 
[71, 72]. 
 
CONCLUDING REMARKS 
 pHLIPs have been shown to target cancer tumor acidity. Targeting that 
exploits acidity, a physical characteristic ubiquitous to tumors, may have advantages 
when compared to other current approaches. Passive targeting, which relies on the 
abnormal vasculature present in large tumors, and active targeting, which relies on 
specific traits of cancer cells, have disadvantages due to the inconsistent presentation 
of passively-targeted traits, the heterogeneity of the cancer cell population, and the 
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presentation of targeted traits in healthy cells. These problems can result in failure to 
target some cancer cells, the selection of resistant tumor cells, and, ultimately, 
ineffective diagnosis, surgery, and therapy due to relapse, the development of 
treatment-resistant cancer, and significant damage to healthy tissue. 
Not only do pHLIPs target both primary tumor tissue and metastases well, but 
the characteristics of the insertion of pHLIPs into cancer cells may make them a useful 
tool for many applications (see Outstanding Questions). pHLIPs have been used to 
tether imaging agents to cell surfaces for diagnostic imaging and fluorescence guided 
surgery. Additionally, the energy of insertion of pHLIPs has been used to deliver 
many different types of cargoes into the cytoplasm: small molecules such as toxins, 
chemotherapeutic agents, and protein fragments; PNA and pDNA for gene therapy; 
and nanomaterials such as liposomes, gold nanoparticles for therapy and imaging, and 
drug-laden porous nanoparticles. The pHLIP family of peptides presents novel 
opportunities in cancer diagnosis and targeted therapy due to the customizable nature 
of the peptides for uses in a wide variety of applications. 
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OUTSTANDING QUESTIONS  
 How can pHLIP® be more effectively used in therapeutic applications? One 
of the greatest strengths of pHLIP® is its ability to deliver polar and moderately 
hydrophobic cargo molecules across the cellular membrane directly into the 
cytoplasm, avoiding the endocytotic pathway and reducing drug resistance. 
Optimized pHLIP® drug conjugates could be extremely useful in therapeutic 
applications, especially for the treatment of metastatic cancers and cancers which 
are difficult to treat, such as triple-negative breast cancers, pancreatic cancer, 
infiltrating and diffusive glioblastomas, and potentially many others. 
 How can pHLIP® and/or the link between peptide and cargo be optimized to 
exclusively target cancer cells in order to achieve intracellular delivery of 
highly toxic cargoes? Off-target delivery of highly toxic chemotherapeutic agents 
(e.g., amanitin) has serious consequences and should be reduced even if the 
number of molecules delivered to the target tissue is consequently reduced. 
Typically, the delivery of just a few very potent drug molecules is enough to 
induce a cytotoxic effect.  
 How can pHLIP® and/or the link between peptide and cargo be optimized for 
the efficient intracellular delivery of large quantities of less toxic cargoes? For 
some cargoes, like those which alter gene expression (e.g., PNA), the cargo itself 
is very specific to its target within cancer cells, and off-target delivery does not 
pose significant problems. At the same time, these types of cargoes need to be 
delivered in larger quantities to induce a noticeable biological effect. 
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GLOSSARY  
Amphipathic pore-forming peptides: Peptides possessing both hydrophobic and 
hydrophilic regions that insert and assemble to form pores in the cellular membrane 
Cell-penetrating peptide (CPP): A peptide, typically with a strong positive charge, 
that binds to the phospholipids of the cell membrane and is taken up by the cell  
Drug-like molecule: A molecule that exhibits properties similar to those of 
established drugs; for example, per Lipinski’s Rule of Five: no more than five 
hydrogen bond donors, no more than ten hydrogen bond acceptors, molecular weight 
below 500 Da, and an octanol-water partition coefficient log P ≤ 5 
F-actin: Filaments that are part of the cell cytoskeleton and contribute to structural 
stability and cell movement 
ICG (indocyanine green): An FDA-approved fluorescent dye used to mark blood 
vessels in angiography and perfusion diagnostics, but does not target the tumor itself 
MicroRNA: Small molecules of RNA that play a functional role in gene expression 
by blocking messenger RNA translation  
Non-standard amino acids: Amino acids that are not encoded in the human genome 
PAR1 (proteinase-activated receptor 1): A member of the large family of G protein-
coupled receptors that plays a functional role in the blood coagulation process 
Passive diffusion: The ability of molecules to cross cell membranes on their own  
Passive targeting methods: Targeting methods that rely on naturally-occurring 
biological characteristics, such as non-intact tumor vasculature, to induce the 
localization of cargo within a tumor 
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Peptide nucleic acid (PNA): Artificial DNA- or RNA-like molecule with a peptide 
backbone that forms a sequence-specific base-paired complex with DNA or RNA 
pHLIP®: The pH (low) insertion peptide; pHLIP is a registered trademark 
Positive margin: The condition that exists after surgical resection when the surgery 
was not successful in removing all cancerous tissue 
RNA polymerase II: A key enzyme that catalyzes transcription  
SNARF (seminaphtharhodafluor): A fluorescent dye with two pH-dependent 
emission peaks, making possible the use of SNARF to measure pH through 
spectrography or ratiometric imaging  
Tissue factor (TF): Protein that is exposed to the blood upon tissue damage, 
triggering blood clot formation 
Tubulin: A family of proteins that polymerize into microtubules, which are part of the 
cytoskeleton and contribute to structural stability, cytoplasmic transport, cell 
movement, and cell division 
Transmembrane helix: The formation by a polypeptide of a helix that spans the lipid 
bilayer of a cellular membrane 
Triple-negative breast cancer (TNBC): Any breast cancer that does not express the 
estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2 
(HER2/neu), making TNBC more difficult to treat due to the reliance of typical 
chemotherapies on the expression of one or more of these receptors  
Tumor invasion: The spread of cancer cells (metastasis) from the primary tumor site 
to adjacent tissue or blood 
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FIGURES 
 
Figure 1. pHLIP membrane interaction and insertion. The peptides of the pHLIP 
family (blue) exist in equilibrium between solvated and membrane-adsorbed 
conformation at the normal extracellular pH found in healthy tissue, whereas peptides 
insert across cellular membrane at the low extracellular pH found in acidic, diseased 
tissue. 
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Figure 2. Mechanism of pHLIP insertion into the cellular membrane. When the 
pHLIP (blue) encounters healthy tissue where the extracellular pH is around pH 7.4, 
the protonatable residues of the pHLIP (red circles) remain deprotonated and 
negatively charged, and the peptide resides at or near the hydrophilic surface of the 
cellular membrane. Weakly bound to the membrane, the pHLIP is washed from the 
membrane via normal perfusion and continues to circulate through the body. Cancer 
cells, however, produce excess acidity as a consequence of their malfunctioning 
metabolisms and overexpression of certain surface proteins, and pump these acidic 
byproducts out of the cell interior in order to maintain comfortable conditions inside 
the cell, resulting in the acidification of tumor tissue. When the pHLIP encounters 
tumor tissue, it senses the low extracellular pH at the cancer cell surface (i.e., the 
concentration of protons (cyan circles) at the surface of the cellular membrane is 
high), and the protonatable residues and negatively charged C-terminal carboxyl group 
of the pHLIP become neutrally charged (green circles). The protonation leads to an 
increase in the overall hydrophobicity of the pHLIP, increasing the affinity of the 
peptide to the hydrophobic core of the cellular membrane and triggering the pHLIP to 
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spontaneously fold into a helix and insert across the membrane, resulting in the 
formation of a transmembrane helix. When the C-terminal protonatable residue and 
carboxyl group are then exposed to the normal intracellular pH of the cell, they are 
deprotonated, again becoming negatively charged, and anchor the pHLIP in the 
membrane. 
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Figure 3. Two uses for pHLIPs: tethering cargo to the cell surface or 
translocating cargo across the membrane into the cytoplasm. A pHLIP (blue) can 
be used to target and tether cargo molecules to the surfaces of cells in low pH 
environments (A). The cargo could be an optical marker, a PET or SPECT imaging 
agent, or an antigen or protein delivered to induce certain cellular processes. A pHLIP 
can also be used for the intracellular delivery of payloads, translocating cargo (green) 
across the membranes of cells with low extracellular pH, such as those cells found in 
acidic, diseased tissue (B). These payloads are conjugated to the membrane-inserting 
end of the pHLIP, typically via a cleavable link (magenta), and could include toxins, 
chemotherapeutic agents, or agents to alter gene expression. 
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Figure 4. A postulated pathway for fusion and cellular uptake of pHLIP-coated 
liposomes. pHLIP-coated liposomes interact with the membrane and promote either 
direct fusion with the lipid bilayer of the membrane (A), or uptake via the endocytotic 
pathway (B), followed by fusion with the endosomal membrane. Both uptake 
mechanisms result in the cytoplasmic delivery of encapsulated polar cargo (green), or 
delivery of lipid membrane-incorporated hydrophobic payloads to the membrane 
(red). Schematic is not to scale. 
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BOXES 
Box 1. Peptides of the pHLIP family share the same features in their primary 
sequences (Figure I) and exhibit the same mechanism of action (Figure 2). These 
shared characteristics include: i) an N-terminal region (flanking sequence 1) that 
varies from 3 to 20 residues and consists mainly of polar amino acids that contribute to 
the overall solubility of the peptide and are used for conjugation with cargo destined 
for the extracellular space; ii) a middle region (transmembrane sequence) that varies 
from 15 to 25 residues and consists mainly of hydrophobic residues, but also includes 
amino acids that are negatively charged at physiological pH but become neutrally 
charged at low pH due to protonation; and iii) a C-terminal region (flanking sequence 
2) that varies from 0 to 10 residues and may contain a few additional protonatable 
residues, as well as residues for conjugation with cargo that will be delivered across 
the cellular membrane to the cytoplasm. Single cysteine and/or lysine residue can be 
used for conjugation with cargo molecules and can be introduced into one or both 
flanking sequences. 
These features are reflected in the sequences of the wild-type (WT) and the Variant 3 
(Var3) pHLIPs, seen below, where protonatable residues are shown in red and the 
putative transmembrane region is underlined: 
WT: AEQNPIY WARYADWLFTTPLLLLDLALLVDAD EGT 
Var3: ADDQN PWRAYLDLLFPTDTLLLDLLW 
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Figure I. The main features of sequences of the pHLIP peptide family. Members 
of the peptide of pHLIP family follow a similar pattern in terms of peptide sequence: 
an N-terminal flanking region (yellow) consists mainly of polar residues; a 
transmembrane region (red) consists mainly of hydrophobic residues, but also includes 
protonatable residues which prevent insertion at physiological pH; and a C-terminal 
flanking region (green), which may not present in all peptides, contains a few 
additional protonatable residues. Cargo can be conjugated either to the C- or N-
terminus via single cysteine or lysine residues. 
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Box 2. Not only can pHLIP conjugates be constructed in a one-to-one ratio between 
pHLIP (blue) and cargo (red), but the pHLIP can also be used to coat molecules in 
order to increase biocompatibility, targeting, and to induce cellular uptake (Figure II). 
Nanoparticles, for instance, have a wide variety of uses in medical applications, 
including as drug-laden nanocarriers, as particles that enhance another form of 
therapy, and as therapeutic agents themselves. Decorating nanoparticles with multiple 
pHLIPs not only results in targeting specificity and greater uptake by cells in acidic, 
diseased environments, but can also bestow biocompatibility on what might be an 
otherwise non-biocompatible nanoparticle. pHLIPs could be used as decorations on a 
wide variety of nanoparticles, and have already been studied in lipid, polymer, and 
metal-based nanomaterials. 
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Figure II. pHLIP delivery capability. pHLIPs are used to increase the tumor 
targeting and delivery of various types of cargoes, such as imaging agents and 
therapeutics, by conjugating cargo to pHLIP in a one-to-one ratio (A). pHLIPs can 
also be used to decorate nanoparticles (B), to increase the biocompatibility, tumor 
targeting and promote cellular uptake of nanoparticles by cancer cells. 
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ABSTRACT 
pH (low) insertion peptides (pHLIP peptides) target acidic extracellular environments 
in vivo due to pH-dependent cellular membrane insertion. Two variants (Var3 and 
Var7) and wild-type (WT) pHLIP peptides have shown promise for in vivo imaging of 
breast cancer. Two positron emitting radionuclides (
64
Cu and 
18
F) were used to label 
the NOTA- and NO2A-derivatized Var3, Var7, and WT peptides for in vivo 
biodistribution studies in 4T1 orthotopic tumor-bearing BALB/c mice. All of the 
constructs were radiolabeled with 
64
Cu or [
18
F]-AlF in good yield. The in vivo 
biodistribution of the 12 constructs in 4T1 orthotopic allografted female BALB/c mice 
indicated that NO2A-cysVar3, radiolabeled with either 
18
F (4T1 uptake; 8.9 ± 
1.7%ID/g at 4 h p.i.) or 
64
Cu (4T1 uptake; 8.2 ± 0.9%ID/g at 4 h p.i. and 19.2 ± 1.8% 
ID/g at 24 h p.i.), shows the most promise for clinical translation. Additional studies to 
investigate other tumor models (melanoma, prostate, and brain tumor models) 
indicated the universality of tumor targeting of these tracers. From this study, future 
clinical translation will focus on 
18
F- or 
64
Cu-labeled NO2A-cysVar3. 
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INTRODUCTION 
Cancer cells, in general, prefer the glycolytic pathway of energy production as a 
consequence of their deregulated proliferative machinery and requirement for survival, 
which results in excess acidity. To maintain homeostasis, cancer cells release lactic 
acid, formed during glycolytic processes, to the extracellular environment.(1-3) The 
release of acid lowers the extracellular pH immediately surrounding these cells 
relative to the pH of normal tissues. Due to the differential in pH gradients, a probe 
marking these acidic regions in rapidly proliferating tissues can potentially distinguish 
cancerous from normal tissue. 
 
The family of pH (low) insertion peptides (pHLIP peptides) represents a novel class of 
delivery agents which can target acidic malignant tissue.(4, 5) The molecular 
mechanism of targeting is based on the pH-dependent formation of a transmembrane 
α-helix, which is accompanied by the insertion of pHLIP peptides into the cellular 
membrane in environments with low extracellular pH (Figure 1).(6) Among 
investigated pHLIP variants, three were under consideration for clinical translation: 
wild-type (WT), variant 3 (Var3), and variant 7 (Var7).(7) 
 
To date, pHLIP peptides have been conjugated to organic dyes or positron-emitting 
radioisotopes for in vitro and in vivo studies.(7-11) Viola-Villegas et al. showed that 
DOTA-pHLIP variants were able to target PC3-WT cancer cells in a pH-dependent 
manner using 
68
Ga-DO3A-cysWT and 
68
Ga-DO3A-cysVar7.(12) Additionally, 
64
Cu-
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NOTA-Var7 showed in vivo localization that was inversely related to measured 
extracellular pH (pHe), but with limited overall tumor uptake (1.36 ± 0.43%ID/g).(12) 
 
The selection of NOTA as the chelator in the present studies opened opportunities to 
explore radiolabeling strategies with a variety of positron-emitting radiometals, as well 
as with 
18
F, for positron emission tomography (PET) imaging.(13-16) As the previous 
studies with pHLIP-PET radiopharmaceuticals in preclinical models established the 
proof-of-principle that the pHLIP platform can indeed selectively target and image 
tumor acidosis, our goals have now advanced to performing first-in-human trials. It 
was first imperative, however, to optimize the tracer (increasing accumulation in the 
tumor with a concomitant clearance from nontarget tissues) by careful selection of the 
optimal radioisotope and pHLIP peptide variant combination prior to commencing 
clinical studies. 
 
In this current study, we investigated and compared the pharmacokinetic properties of 
six pHLIP constructs (NOTA-WT, NOTA-Var3, NOTA-Var7, NO2A-cysWT, NO2A-
cysVar3, and NO2A-cysVar7) labeled with two different PET isotopes (
64
Cu and 
18
F) 
using an orthotopic breast cancer model (murine 4T1 mammary adenocarcinoma, a 
model of human stage IV breast cancer) through ex vivo biodistribution and in vivo 
imaging studies. In addition, the biophysical measurements of the nonradioactive, 
metalated peptides were conducted to help explain the variations observed in the 
animal studies. From these studies, two lead radiopharmaceuticals (
18
F-AlF-NO2A-
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cysVar3 and 
64
Cu-NO2A-cysVar3) were selected and further assessed in melanoma, 
prostate, and brain tumor models. 
 
RESULTS 
Preparing the Radiotracers 
The NOTA (1,4,7-triazacyclononane-N′,N″,N‴-triacetic acid) chelator was conjugated 
to the pHLIP variants in two ways (Figure 2). The NOTA-pHLIP compounds contain 
NOTA with three carboxylic acid groups conjugated to the N-terminus of the peptide 
(Figure 2A). The NO2A-cyspHLIP compounds contain NOTA with two carboxylic 
acid groups, where the third group was used to conjugate the chelator to the peptide 
through the cysteine side chain (Figure 2B). The Cu2+ and AlF2+ NOTA complexes 
have an overall charge of −1 with a neutral charge at the N-terminus of the pHLIP 
peptides. All complexes with the NO2A-chelates have an overall neutral charge with 
the positive charge preserved at the N-terminus of the pHLIP peptides. The three 
peptide sequences are tabulated in Figure 2C. 
 
The 
64
Cu radiolabeling of each of the conjugates was achieved with >60% (isolated) 
yield with >93% purity (Supporting Information); the 
18
F-AlF radiolabeling of each of 
the conjugates was 4–50% (isolated and decay corrected to start of synthesis) yield 
with >95% purity (Supporting Information). Table S1 lists the specific activity of 
each radiolabeled pHLIP peptide. 
 
In Vivo Studies in 4T1 Tumor Models 
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Direct evaluation of all 12 tracers in vivo was carried out in 4T1 orthotopic (surgically 
implanted) allografted female BALB/c mice in order to determine which compounds 
would be best translated into clinical studies. Figure 3 shows the in vivo PET imaging 
slices at the level of the tumor at 4 h p.i. of 11 of the 12 tracers tested and the ex vivo 
biodistribution in selected organs at 4 and 24 h p.i. (%ID/g, mean ± S.D.). The 
corresponding maximum intensity projections (MIPs) from the PET imaging study 
and the PET imaging slices at the level of the tumor with a lower maximum value for 
better visualization of the tumor at 4 h p.i. for the 
18
F-AlF-NO2A-cyspHLIP constructs 
are collected in Figure S1. The 4 h ex vivo biodistribution values (%ID/g, mean ± 
S.D.) are collected in Tables 1 and 2 for all 12 radiopharmaceuticals, and the complete 
biodistribution results for all time points are tabulated in the Supporting 
Information (Tables S1–1 through S13–14). Due to the ex vivo biodistribution data 
for 
64
Cu-NOTA-Var7 and the previous results from the imaging study of the other 
NOTA-pHLIP constructs, an additional imaging study for 
64
Cu-NOTA-Var7 was 
unjustified. These data clearly indicate that all constructs with the NO2A chelator far 
outperform the constructs with the NOTA chelator. It appears that NO2A-cyspHLIP 
constructs have a longer blood half-life, which results in higher targeting and longer 
retention within the tumor while the radiopharmaceutical clears from nontarget tissues 
and the blood. 
 
Biophysical Studies 
With 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes as model 
membranes, our comparative biophysical investigation of the pH-dependent 
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interaction of NOTA-pHLIP and NO2A-cyspHLIP constructs with the lipid bilayer 
indicated that NOTA constructs adopt unfavorable conformations at the membrane 
surface at physiological and low pH compared to NO2A constructs. Although 
biophysical measurements are typically conducted in solutions without the further 
addition of ions, we chose to investigate the performance of these constructs in both 
the absence and the presence of physiological levels of free magnesium and calcium 
ions. Wild-type constructs appear to be sensitive to the presence of divalent cations, 
most likely due to the multiple protonatable aspartic and glutamic acid residues at the 
inserting end of the peptide, which tend to form divalent complexes with these ions at 
physiological pH. Plots demonstrating the changes in fluorescence spectra of AlF-
NOTA-Var3, Cu-NOTA-Var3, AlF-NO2A-cysVar3, and Cu-NO2A-cysVar3 upon 
interaction with membranes are shown in Figure S2. 
 
Figure 3 shows the biodistribution of 
64
Cu- and 
18
F-NO2A constructs in selected 
tissues at 4 and 24 h. As previously reported,(17) Var7 constructs exhibit the fastest 
blood clearance with the highest signal in the kidneys at 4 h p.i. and kidney clearance 
at later time points. Both 
18
F-AlF-NO2A-cysWT and 
64
Cu-NO2A-cysWT have 
slightly higher liver and spleen uptake compared to the corresponding cysVar3 and 
cysVar7 conjugates. All of the NO2A constructs demonstrate a pH-dependent 
interaction with the lipid bilayer of the cellular membrane (Figures S3 and S4), but 
the NO2A-cysWT constructs exhibit the highest affinity to the lipid membrane at 
physiological pH. Additionally, the pK of transition from the membrane-bound state to 
the inserted state is higher for NO2A-cysWT constructs compared with NO2A-
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cysVar3 and NO2A-cysVar7 constructs. This shift in pK is most likely responsible for 
the higher uptake of the NO2A-cysWT constructs by the liver and spleen. 
 
Both 
64
Cu-NO2A-cysVar3 and 
18
F-AlF-NO2A-cysVar3 had the highest tumoral 
uptake, prolonged retention in the tumor, and minimal accumulation in other organs 
based on the ex vivo biodistribution data. Figure 4 shows the pH-dependent insertion 
and tabulates the percentage of the NO2A-cysVar3 construct population that is 
inserted in the membrane at various pHs. The results indicate that less than 5% of the 
lead compounds should be inserted into the membrane at pH 7.4 (physiological pH), 
whereas greater than 25% of the NO2A-cysVar3 compounds should be inserted into 
the cellular membrane at pH 6.0 (the approximate pH at the surface of cancer cells). In 
addition, the membrane insertion of Var3 and Var7 takes place at a rate 2 orders of 
magnitude higher than the rate of insertion of WT.(17) 
 
In Vivo Studies in Prostate, Melanoma, and Brain Tumor Models 
The two NO2A-cysVar3 compounds that showed superior targeting of the 4T1 tumors 
were compared in melanoma and prostate cancer models. Figure 5 shows the in vivo 
PET images of the uptake of the two tracers in tumors at 4 and 24 h p.i. The graph 
in Figure 6 directly compares the tumoral uptake of the two lead compounds at 4, 6, 
and 24 h p.i. for four of the tumor models investigated in this study. Due to the large 
variation in tumor size for the LNCaP tumors, the ex vivo data shows a minimal 
increase in tumoral uptake over the PC3 tumors, but both the murine B16–F10 
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melanoma tumors and 4T1 breast cancer tumors showed greater uptake of the tracers 
compared to the human prostate cancer models. 
 
Because of the low uptake of the tracers in brain tissue, the 
18
F-AlF-NO2A-cysVar3 
was also evaluated in U87MG tumor-bearing mice. These tumors were implanted into 
the brain cavity or xenografted subcutaneously on the flank of nude mice. Figure 
S5 shows the imaging of these tumors. The uptake in the U87MG tumors that were 
implanted into the brain cavity showed significant uptake of the tracer in the portion of 
the tumor that was outside the skull. During necropsy, these tumors did not show 
significant infiltration of the brain. The ex vivo biodistribution of 
18
F-AlF-NO2A-
cysVar3 at 6 h p.i. in the nude mice with flank tumors is included in Figure S5. In 
order to conclusively determine if the uptake of 
18
F-AlF-NO2A-cysVar3 was only in 
the portion of the tumor outside of the skull, a group of mice with GSC 5–22 tumors 
orthotopically xenografted behind an intact blood-brain barrier (BBB) were obtained. 
During necropsy, these tumors had infiltrated half of the brain, but there was no 
uptake observed in the PET image (Figure S5). 
 
Specific Activity Investigation 
The tracers were prepared to have comparable specific activities (approximately 100 
μCi/nmol (3.7 MBq/nmol)) for most of the studies. A few additional studies were 
conducted with higher and lower specific activities in order to compare the effect of 
specific activity on tumoral uptake. The data sets were analyzed individually and 
showed that specific activity did not impact the biodistribution of the tracers, 
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especially tumoral uptake. Thus, all of the data points for similar tumor models were 
averaged in aggregate (regardless of specific activity) and tabulated together in 
the Supporting Information. 
 
Tissue Autoradiography 
The uptake of 
64
Cu-NO2A-cysVar3 (24 h p.i.) in LNCaP and PC3 tumors was 
investigated via autoradiography with viable tissue stained with hematoxylin and eosin 
(H&E) to determine if the uptake was specific to regions showing indications of 
metabolic stress or necrosis. Interestingly, uptake of 
64
Cu-NO2A-cysVar3 appears to 
correlate with necrotic regions in LNCaP tumors, but not in PC3 tumors (Figure 7). 
This could be a result of the PC3 tumors having less necrosis overall than the LNCaP 
tumors in this study. Additionally, the autoradiography shows increased relative 
uptake of 
64
Cu-NO2A-cysVar3 (24 h p.i.) in LNCaP over PC3 tumors (Figure S6). 
This finding is similar to the results from previous studies by our group, in which both 
LNCaP and PC3 tumors were investigated.(10-12) H&E staining of tumor sections 
from 4T1 tumors excised 5–12 days post-inoculation show non-necrotic tumor tissue; 
thus, the greater tumoral uptake of the 
64
Cu-NO2A-cysVar3 (according to the ex vivo 
biodistribution data) does not appear to be correlated to necrosis. 
 
DISCUSSION 
Two positron-emitting radionuclides (
18
F and 
64
Cu) can be used to label NOTA-
peptides for in vivo imaging. While 
64
Cu (t1/2 = 12.7 h) has a moderately short half-life, 
the production of 
64
Cu requires a higher energy cyclotron and expensive targetry with 
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automated radionuclidic separation which many institutions do not currently have. 
Conversely, 
18
F (t1/2 = 109.8 min) is readily available from most medical cyclotrons 
and radiopharmaceutical centers, is routinely produced at numerous sites worldwide, 
and can be inexpensively concentrated for radiolabeling. Unlike conventional 
nucleophilic 
18
F labeling of small organic molecules, using a chelator to coordinate the 
aluminum center of [
18
F]-AlF is straightforward and can be done in aqueous 
solution.(15, 16) 
 
After the radiopharmaceuticals were successfully synthesized, their ability to target 
cancerous tissue was directly compared in 4T1 tumor-bearing female BALB/c mice. 
This model of triple-negative human stage IV breast cancer was chosen based on 
previous findings in our group that the pHLIP-PET agents were excreted through both 
the hepatobiliary and renal pathways and showed very good tumor:muscle ratios.(10-
12) As such, breast cancer seemed an appropriate target which is imaged in humans 
away from these excretion organs. Additionally, previous results from Serganova et al. 
indicated that the pH of 4T1 tumors increases with increased size.(18) Thus, the 4T1 
tumors in this study were purposely used 5–7 days after inoculation to ensure lower 
tumoral pH. The ex vivo biodistribution data show that the metalated NOTA-pHLIP 
variants are quickly cleared via both the hepatobiliary and renal pathways to reduce 
the overall circulating radioactivity significantly by 12 h p.i. The rapid excretion of 
the 
64
Cu-NOTA-pHLIP variants from the intestines and slow elimination from the 
kidneys over time indicate that the compounds are not being taken up by the cells 
within these organs, but are being eliminated via these pathways. Additionally, when 
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comparing the 2 h ex vivo data for kidneys-to-large intestine ratios [
64
Cu-NOTA-WT 
is 0.35 ± 0.11; 
18
F-AlF-NOTA-WT is 0.42 ± 0.03; 
64
Cu-NOTA-var3 is 0.29 ± 
0.12; 
18
F-AlF-NOTA-var3 is 0.52 ± 0.15; 
64
Cu-NOTA-var7 is 0.32 ± 0.07; 
18
F-AlF-
NOTA-var7 is 0.55 ± 0.19], there is no significant difference between the excretion 
pathways of variants radiolabeled with 
64
Cu or 
18
F. Perhaps the charge of the 
complexes appended to the pHLIP peptides helps to improve the elimination of these 
compounds, but also decreases the likelihood of uptake in low pH environments, such 
as the tumor, which may require more residence time in the blood. The lack of tumor 
targeting is evident in the imaging study results shown in Figure 3. 
 
Conversely, the neutrally charged NO2A complexes conjugated to the cysteine residue 
of pHLIP peptides (which preserve their positive charge at the N-terminus) show 
prolonged blood circulation with slower clearance, consequently leading to better 
perfusion of the tracers in the tumor microenvironment where they are effectively 
trapped. The steady increase of the tumoral uptake of each of the tracers implies slow 
localization in the tumor site. The radiometalated NO2A-cysVar7 compounds had the 
shortest blood retention with similar tumoral uptake at 4 h to the other radiolabeled 
compounds. This rapid blood clearance may make the radiometalated NO2A-cysVar7 
compounds useful for shorter imaging times (tumor is visible in the slices at the tumor 
level in Figure S1) as long as the tumor is sufficiently distant from the kidneys (the 
major organ visible in the MIP in Figure S1). The rapid clearance of the Var7 
constructs (noted in previous studies(17, 19)) may be a function of their physical 
characteristics. While these compounds have pKs of insertion similar to the NO2A-
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cysVar3 constructs, they are less hydrophobic than the NO2A-cysVar3 constructs. 
This lower hydrophobicity results in faster blood clearance (indicated by lower 
amounts of NO2A-cysVar7 constructs in the blood at every time point). The lower 
amount of radiolabeled compound in the blood for longer periods of time may result in 
lower tumoral uptake of the NO2A-cysVar7 constructs because the targeted tissue is 
exposed to less of the construct. At the same time, NO2A-cysWT compounds 
exhibited highest accumulation in liver and spleen compared to NO2A-cysVar3 and 
NO2A-cysVar7, most probably due to their higher membrane affinity (greater 
hydrophobicity) at physiological pH and slower rate of membrane 
insertion.(17) Additionally, the 
64
Cu-NO2A-cyspHLIP derivatives show decreased 
radioactivity accumulation in the kidney from 4 h p.i. to 24 h p.i. which is due to 
clearance of the drug rather than uptake, whereas the liver and spleen uptake remains 
similar for the two time points. The liver and spleen uptake may be due to loss of 
the 
64
Cu from the chelator,(20) digestion of the radiotracer in vivo, or accumulation of 
intact tracer in these organs. Further investigation of this uptake is currently underway 
by investigating a pHLIPcys-NO2A derivative that contains the cysteine residue on 
the internalized portion of the peptide (C terminus), which could result in lower liver 
and spleen uptake if the uptake in these organs is due to loss of the 
64
Cu from the 
chelator after membrane insertion. 
 
From these results it becomes evident that introducing a benzene ring in close 
proximity to the N-terminus of the peptide sequence and using a negatively charged 
metal complex should be avoided in pHLIP peptide-mediated tumor imaging 
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pharmaceuticals. Instead, conjugating to either the cysteine side chain or utilizing a 
suitable linking group on the N-terminus may improve tumor targeting of the 
synthesized pHLIP peptide. These general guidelines may help explain the 
improvements seen in this study and understand the results from previous studies. 
 
Two compounds from the 12 tracers included in this study showed the greatest 
tumoral uptake and significant tumor-to-background contrast in the images throughout 
the imaging studies: 
64
Cu-NO2A-cysVar3 and 
18
F-AlF-NO2A-cysVar3. Therefore, we 
next investigated the in vivo properties of these two tracers in PC3 and LNCaP tumor-
bearing mice to compare tumoral uptake with previous studies.(10-12) In these tumor 
models, the tumor accumulation of 
64
Cu-NO2A-cysVar3 and 
18
F-AlF-NO2A-cysVar3 
was significantly higher compared to previous generations of PET isotope-labeled 
pHLIP constructs, especially at 24 h p.i. (Figure S7). Of particular note is the uptake 
of the 
18
F-py-click-6Ahx-WT reported by Daumar et al.(11) and 
68
Ga-DO3A-cysVar7 
reported by Viola-Villegas et al.(12) Both of these previously reported compounds 
show significant uptake at 4 h p.i. and could be clinically useful. By comparison of the 
tumor:tissue ratios with those of previously reported compounds (Figure S8), the 
tumor:muscle ratios at 4 h p.i. were 7.4 ± 1.3 (
64
Cu-NO2A-cysVar3), 6.9 ± 1.9 (
18
F-
AlF-NO2A-cysVar3), 4 ± 2 (
18
F-py-click-6Ahx-WT), and 1.1 ± 1.5 (
68
Ga-DO3A-
cysVar7) in PC3 tumor-bearing male nude mice; the tumor:bone ratios were 2.7 ± 0.6 
(
64
Cu-NO2A-cysVar3), 3.2 ± 0.7 (
18
F-AlF-NO2A-cysVar3), 1.3 ± 0.4 (
18
F-py-click-
6Ahx-WT), and 0.4 ± 0.3 (
68
Ga-DO3A-cysVar7) in PC3 tumor-bearing male nude 
mice. Additionally, the tumor:muscle ratios in LNCaP tumor-bearing male nude mice 
  
 
 
53 
at 4 h p.i. were 6 ± 2 (
64
Cu-NO2A-cysVar3), 4.7 ± 0.9 (
18
F-AlF-NO2A-cysVar3), and 
6 ± 3 (
18
F-py-click-6Ahx-WT); the tumor:bone ratios in LNCaP tumor-bearing male 
nude mice at 4 h p.i. were 4.2 ± 1.7 (
64
Cu-NO2A-cysVar3), 4.3 ± 1.1 (
18
F-AlF-NO2A-
cysVar3), and 1.8 ± 0.6 (
18
F-py-click-6Ahx-WT). In each of these cases, the tumor 
ratios of the two lead compounds from this study are much better than the 
68
Ga-
DO3A-cysVar7, which would result in improved image contrast. While the 
18
F-py-
click-6Ahx-WT had similar tumor:muscle ratios, the tumor:bone ratios were much 
lower than the two lead compounds in both prostate cancer tumor models. The 
decreased tumor:bone ratios may indicate that the previously reported 
18
F-py-click-
6Ahx-WT was more prone to defluorination than the 
18
F-labeled tracers presented in 
this study. 
 
Despite the similar tumor-targeting properties, the preparation of 
18
F-py-click-6Ahx-
WT requires two HPLC-based separations and generates a volatile radioactive 
intermediate. The preparation of either of the lead compounds from this work, in 
contrast, did not required HPLC purification or heating beyond 80 °C which is optimal 
for rapid dose-on-demand production of the tracers for patient trials. Thus, the two 
lead compounds from this study appear to be the best candidates for clinical 
translation because of their improved biopharmaceutical properties and facile 
radiosynthesis. 
 
Two other tumor types (melanoma and glioma) were included in this study to 
determine if the high uptake of these radiotracers seen in breast and prostate cancer 
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models would translate to other types of tumors. The lead compounds have excellent 
tumor:background contrast in B16–F10 murine melanoma tumor-bearing mice, which 
was useful to identify very small tumors (<17 mg; ∼4 mm3) in the PET image. 
Because of the contrast and high uptake, we plan to continue investigating the use of 
the two lead compounds in metastatic B16–F10 tumor models. For the brain tumor 
models, both an orthotopic and a subcutaneous (flank) brain tumor mouse model 
indicated that the 
18
F-AlF-NO2A-cysVar3 was unable to penetrate an intact BBB, but 
was able to target brain tumors that had developed outside the BBB (Figure S5). 
Because this is a peptide-based tracer, we did not expect the compound to be able to 
cross an intact BBB; thus, these tracers may be useful in identifying metastases and 
possibly brain tumors in situations of compromised BBBs. 
 
Previously, autoradiography was performed by Viola-Villegas et al. in prostate tumor 
sections from excised PC3 and LNCaP tumors in order to show differences in 
histology and tracer uptake;(12) thus, a similar study was performed with the uptake 
of 
64
Cu-NO2A-cysVar3 in the same tumor lines. Overall, the ex vivo tumor sections 
show increased uptake of the 
64
Cu-NO2A-cysVar3 in the necrotic regions of the 
LNCaP tumors (Figure 7). This may indicate that if necrosis is present, then uptake 
of 
64
Cu-NO2A-cysVar3 may increase, but is not the only requirement. The findings 
here generally match the trend found by Viola-Villegas et al. in prostate tumor 
sections.(12) Additionally, the greater uptake in the allografted tumors may indicate 
the relative overall tumor environment is less acidic (higher) in the slower growing 
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human cell lines investigated (PC3 and LNCaP), but is more acidic (lower) in the 
faster growing murine cell lines (B16–F10 and 4T1). 
 
EXPERIMENTAL SECTION 
The D-amino acid versions of NOTA-derivatized pHLIP peptides were purchased 
from CS Bio (Menlo Park, CA) with ≥95% purity (combination of both chelators and 
three variants from Figure 2: NOTA-WT, NOTA-Var3, NOTA-Var7, NO2A-cysWT, 
NO2A-cysVar3, and NO2A-cysVar7). All other chemicals were purchased from 
commercial suppliers without further purification unless otherwise stated. Detailed 
method descriptions are found in the Supporting Information. 
 
Radiochemistry 
General Labeling Methods for 
64
Cu-NOTA-pHLIP 
Following a preparation similar to that of Zeglis et al.,(21) 
64
Cu was diluted in a 100 
mM NH4OAc buffer (pH ∼ 5.5) and reacted with a NOTA-pHLIP derivative at 80 °C 
for 15 min. 
 
General Labeling Methods for 
18
F-AlF-NOTA-pHLIP 
Following a modified labeling method described by Dijkgraaf et al.,(22) 
18
F from the 
cyclotron target water was concentrated using a chromafix cartridge into 0.1 mL of 0.4 
M KHCO3 in metal-free water. The pH was adjusted and 0.1 mL AcN added. To this 
solution, AlCl3 (80 nmol) in 0.1 M NH4OAc buffer (pH ∼ 4.1) was added. After 5 
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min, the NOTA-pHLIP derivative was added and the reaction mixture reacted at 75 °C 
for 15 min. 
 
General Purification 
An Oasis HLB Plus Light or C18 Sep-Pak Light cartridge (Waters, Milford, MA) was 
used to remove unbound activity. The pure radiolabeled NOTA-pHLIP derivatives 
were eluted with EtOH and diluted with sterile phosphate buffered saline (PBS) with 
radiochemical purities >93% before administration to animals. 
 
Animal Models 
Animal studies were conducted according to an MSKCC IACUC-approved animal 
protocol. 4T1 (orthotopic breast cancer allografts of 1 × 106 cells surgically implanted 
in the mammary fat pad) and B16–F10 (orthotopic melanoma allografts of 1 × 
105 cells injected intradermally on the shoulder) tumors were orthotopically 
inoculated in media in female BALB/c and C57Bl/6 mice (Charles River Laboratories 
(CRL)), respectively. Additionally, PC3 (3 × 106 cells) or LNCaP ((3–6) × 106 cells) 
tumors were subcutaneously xenografted on the shoulder of athymic nude male mice 
(CRL). Mice were used once tumor volumes were approximately 90–300 mm3. 
 
In Vivo Animal PET Imaging and Biodistribution 
Mice were injected with radiolabeled NOTA-pHLIP derivatives i.v. (500–700 
μCi/mouse for PET imaging studies and 25–100 μCi/mouse for biodistribution 
studies). All injections were less than 200 μL with <10% EtOH in sterile PBS. PET 
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images were obtained with the mice under anesthesia in an Inveon PET-CT or 
microPET Focus 120 (Siemens) at 0.5–48 h p.i. All images were analyzed using 
ASIPro VM (Concorde Microsystems). Dissections for ex vivo biodistribution were 
performed on mice after CO2 asphyxiation or cervical dislocation while anesthetized 
at reported time points. Weight of the syringe prior to injection and after injection was 
used to determine the mass of injectate. Activity of the syringe prior to injection and 
after injection was used to determine the percent of injectate administered. The mass 
injected was corrected by the percent of radioactivity injected. Four to five aliquots 
(10 μL) were weighed and counted as internal standards for each study. All of the 
collected organs were counted using an automatic gamma counter (Wizard 3″, 
PerkinElmer, Waltham, MA). The total injected dose was found as the mass injected 
dose × fraction radioactivity injected × internal standard average counts/g. The percent 
injected dose (%ID) was determined as the counts for the tissue × 100/total injected 
dose. The %ID/g was calculated as the %ID/tissue weight. The average and standard 
deviation of the %ID and %ID/g was determined using normal methods (n – 1) for 
each set of mice. 
 
Ex Vivo Autoradiography, Staining, and Microscopy 
Tumors were excised from the mouse, embedded into Tissue-Plus O.C.T. (Scigen, 
Gardena, CA), stored at −20 °C until sectioning, and cut in sequential 10 μm sections. 
Select sections were exposed to autoradiography film (Fujifilm, GE Healthcare) for 1–
3 days and read using a typhoon photographic film scanner (GE Healthcare). 
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Additionally, sections were stained with H&E for gross tumor microscopy and then 
scanned. 
 
Biophysical Studies 
Biophysical studies were conducted on nonradioactive standards of the NOTA-pHLIP 
and NO2A-cyspHLIP compounds. All experiments were conducted with a 5 μM to 1 
mM construct to lipid ratio. State I (construct with no liposomes in solution) and State 
II (construct in the presence of liposomes) were measured at pH 8; for State III 
(construct in the presence of liposomes), the pH of solution was dropped to pH 4 using 
2 M HCl. Experiments were conducted in 10 mM phosphate buffer (Sigma-Aldrich) 
either without additional ions or in the presence of physiological levels of free 
magnesium and calcium (0.65 mM and 1.25 mM, respectively). 
 
Liposome Preparation 
Large unilamellar vesicles were prepared by extrusion. 1-Palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC; Avanti Polar Lipids) was dissolved in chloroform 
at a concentration of 12.5 mg/mL, desolvated by rotary evaporation, and dried under 
high vacuum for 2 h. The phospholipid film was then rehydrated in 10 mM phosphate 
buffer (pH 8.0 with or without ions), vortexed, and extruded 15× through a 50 nm 
pore. 
 
Steady-State Fluorescence 
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Tryptophan fluorescence spectra were measured using a PC1 ISS spectrofluorometer 
(Champaign, IL) with temperature control set to 25 °C. Fluorescence spectra were 
recorded with excitation and emission slits set to 1 mm, using an excitation 
wavelength of 295 nm, with excitation and emission polarizers set to 54.7° and 0°, 
respectively. 
 
Steady-State Circular Dichroism 
Circular dichroism measurements were taken using a MOS-450 spectrometer (Bio-
Logic SAS, Claix, France) with temperature control set to 25 °C in the range of 190 to 
260 nm with step of 1.0 nm. 
 
pH Dependence 
The pH-dependent insertion of the construct population was investigated using the 
shift in position of the wavelength of maximum intensity of the tryptophan 
fluorescence spectra varying pH conditions between 4 and 8. The pH after addition of 
HCl was measured using an Orion PerpHecT ROSS Combination pH Micro Electrode 
and an Orion Dual Star pH and ISE Benchtop Meter (Thermo Fisher Scientific). 
Tryptophan fluorescence spectra were recorded at each pH value and were analyzed 
using an online protein fluorescence and structural toolkit (PFAST) to obtain the 
positions of spectral maxima (λmax). Finally, the positions of λmax were plotted as a 
function of the various pHs and the Henderson–Hasselbalch equation employed to fit 
the data , where λmax1 and λmax2 are the positions of spectral 
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maxima at the end and beginning of the State II – State III transition, respectively, n is 
the cooperativity parameter, and pK is the midpoint of transition. 
 
CONCLUSIONS 
In our study, the NO2A-cysVar3 is the lead construct for clinical investigation. This 
construct can be radiolabeled with 
18
F or 
64
Cu with similar pharmacokinetic 
properties. The availability, limited dose exposure due to its short half-life, and cost 
effectiveness of 
18
F supports the utility of 
18
F-AlF-NO2A-cysVar3 in the clinic. 
Nevertheless, 
64
Cu-NO2A-cysVar3 may be more suitable for inpatient imaging (where 
the patient will be in the clinic longer than 24 h) and in centers where the availability 
of the PET scanner may impact the time when patients are imaged. Clinical evaluation 
of these radiopharmaceuticals is currently underway. 
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ABBREVIATIONS 
AcN   acetonitrile 
H&E   hematoxylin and eosin 
MIP   maximum intensity projection 
NOTA   1,4,7-triazacyclononane-N′,N″,N‴-triacetic acid 
pHLIP   pH (low) insertion peptide 
pHLIP-PET  pHLIP radiolabeled with a positron emitting nuclide 
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FIGURES 
 
Figure 1. Three folding states of pHLIP peptides in decreasing extracellular pH: 
unfolded and unbound peptide in solution (State I), unfolded peptide loosely 
interacting with the membrane lipid bilayer at physiological pH (State II), and folded 
peptide in α-helical conformation inserted across the membrane at low extracellular 
pH (State III). 
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Figure 2. Two chelators [(A) NOTA-pHLIP and (B) NO2A-cyspHLIP] and (C) the 
peptide sequences used in this study. The chiral centers within the chelator and linker 
are marked with asterisks. 
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Figure 3. Coronal PET image slices at the level of the tumor at 4 h p.i. (A) and ex 
vivo biodistributions in selected organs at 4 h (B) and 24 h p.i. (C) showing 
differences in the tracer distribution in BALB/c female mice bearing 4T1 tumor 
allografts. The yellow arrowheads in (A) indicate where the tumor is located in the 
mouse. The selected scale on the PET images does not allow for tumor visualization in 
the case of the NO2A-cysVar7 constructs. Figure S2 shows the maximum intensity 
projections (MIPs) for these compounds at 4 h and the slices at the level of the tumor 
for the 
18
F-AlF-NO2A-cyspHLIP constructs with a maximum value of 15%ID/g. Only 
ex vivo biodistribution data was obtained for 
64
Cu-NOTA-Var7. 
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Figure 4. pH dependent bilayer insertion of NO2A-cysVar3 constructs. Changes in 
intrinsic construct fluorescence are used to measure the insertion of the construct 
population as a function of pH (transition from State II, at high pH, to State III, at low 
pH). Amount of construct population in State II is measured on the y-axis. 95% 
confidence intervals are indicated by yellow bands (A). pH-dependence parameters are 
used to calculate the percent of inserted construct population at various pH levels (B). 
These transitions were measured in the presence of physiological levels of free 
magnesium and calcium ions (0.65 mM and 1.25 mM, respectively). 
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Figure 5. Slices and maximum intensity projections (MIP) from PET images showing 
differences in the radiolabeled NO2A-cysVar3 distribution at 4 and 24 h in BALB/c 
female mice bearing orthotopic 4T1 tumor allografts, nude male mice bearing 
shoulder PC3 or LNCaP xenografts, and C57Bl/6 female mice bearing orthotopic 
B16–F10 tumor allografts. The yellow arrowheads indicate where the tumor is located 
in the mouse. 
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Figure 6. Graph of the ex vivo tumor uptake of the lead radiolabeled NO2A-cysVar3 
in various tumor models at 4, 6, and 24 h p.i. 
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Figure 7. Comparison of uptake in sections of excised tumors from PC3 or LNCaP 
tumor-bearing male nude mice. The top panels are expansions of the whole tumor 
sections shown below. The left-most panels are H&E stained, the middle panels are 
the autoradiography, and the right-most panels are overlays. 
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TABLES 
 
Table 1. Biodistribution (%ID/g) of the Six Radiolabeled N-Terminus Derivatized 
NOTA-pHLIP Derivatives in 4T1 Allografted Female BALB/c Mice at 4 h p.i. 
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Table 2. Biodistribution (%ID/g) of the Six Radiolabeled Cysteine Derivatized 
NO2A-cyspHLIP Derivatives in 4T1 Allografted Female BALB/c Mice at 4 h p.i. 
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SUPPORTING INFORMATION 
METHODS & MATERIALS 
Radiolabeling  
Labeling methods for 
64
Cu-NOTA-pHLIP. Following a preparation similar to Zeglis et 
al.,
1
 3.13-11.26 mCi (116 – 417 MBq) of 64Cu in 0.1 M HCl (2.5-6.0 μL, 1.86×104-
1.25×104 mCi/μmol, Washington University, St. Louis, MO) was added to 150 μL of 
100 mM NH4OAc buffer (pH ~5.5). An aliquot (25-37 μL) of NOTA-pHLIP 
derivative (0.46-0.63 mM) in DMSO was added to the pH adjusted 
64
Cu solution. The 
solution was placed on a thermomixer (Eppendorf, Hamberg, Germany) at 80 °C for 
15 min at 1100 rpm. An aliquot of the crude product mixture was HPLC-analyzed (5-
95 % acetonitrile in water (with 0.1 % trifluoroacetic acid) over 15 min, Jupiter C-18 
column, Phenomenex, 250 mm × 4.6 mm, 5 μm, 300 Å) to ensure that product was 
present (
64
Cu-NOTA-pHLIP eluted at 10.3 min; 
64
Cu-NO2A-cyspHLIP eluted at 13.1 
min). The remainder of the reaction mixture was separated using a pretreated Oasis 
HLB Plus Light or C18 Sep-Pak Light cartridge (Waters, Milford, MA). Free and 
unbound 
64
Cu was removed by washing the cartridge with 5 mL of water. The pure 
64
Cu-labeled NOTA-pHLIP derivatives were then eluted with 1 mL ethanol in 0.1 mL 
fractions. The ethanolic fractions with the highest activities were combined and 
diluted with sterile phosphate buffered saline (PBS) to provide < 10 % ethanol in the 
solution before HPLC analysis (Jupiter C-18, 5 μm, 300 Å, 250 × 4.6 mm, 
Phenomenex; 5-95 % AcN in water with 0.1 % TFA over 15 min at 1 mL/min) to 
ensure that no free 
64
Cu was present. The radiochemical purity of the species was 
always > 93 % and the specific activity (using the original amount of peptide added to 
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the reaction mixture) was estimated to be 56.0-318.4 μCi/nmol (3.05-11.8 GBq/μmol). 
The reaction yielded 1.29-9.54 mCi (47.7-353 MBq) of product with an isolated yield 
of 40.7-84.7 %.  
Labeling methods for 
18
F-AlF-NOTA-pHLIP. Following a modified labeling method 
described by Dijkgraaf et al.,
2
 52.0-60.8 mCi (1.92-2.25 GBq) of 
18
F target water 
(produced from 
18
O enriched target water using a GEMS PETtrace-800 cyclotron, 
Memorial Sloan Kettering Cancer Center, New York, NY) was obtained. The target 
water was loaded onto a preconditioned chromafix cartridge (30-PS-HCO3, Advanced 
Biochemical Compounds (ABX), Germany). [All of the preconditioning solvents and 
the elution solution were prepared with metal-free water and trace-metal free 
reagents.] The 
18
F was eluted from the cartridge with approximately 100 μL of 0.4 M 
KHCO3 in metal-free water into a 1.5 mL tube (ThermoFisher Scientific, Waltham, 
MA). The pH was adjusted to ~4.1 with metal-free acetic acid (Sigma Aldrich). To the 
pH adjusted solution, 100 μL of acetonitrile was added. If the total activity exceeded 
50 mCi (1.85 GBq), the mixture was split between multiple 1.5 mL tubes prior to 
continuing (~10 mCi/40 nmol reaction). To the aliquotted mixture, 20 μL (40 nmol) of 
2 mM AlCl3 in 0.1 M NH4OAc buffer (pH ~4.1) was added to each tube. The solution 
was allowed to react for 5 min at room temperature before 14-17 μL of 4-5 mM 
NOTA-peptide in DMSO (68-75 nmol) was added, the tube capped, and the reaction 
mixture reacted at 75 °C for 15 minutes in a thermomixer. After reaction, the mixture 
was diluted with 2 mL of metal-free water. An aliquot of the reaction mixture was 
HPLC-analyzed (20-95 % acetonitrile in water (with 0.1 % trifluoroacetic acid) over 
15 min with an Atlantis T3, Waters, 250 mm × 4.6 mm, 5 μm; Jupiter, Phenomenex, 
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250 mm x 4.6 mm, 5 μm, 300 Å, column) to ensure that product was formed (18F-AlF-
NOTA-WT eluted between 10.1 and 12.1 min; 
18
F-AlF-NOTA-var3 eluted between 
10.2 and 11.4 min; 
18
F-AlF-NOTA-var7 eluted between 8.2 and 10.3 min; 
18
F-AlF-
NOTA-cysWT eluted between 13 and 16 min; 
18
F-AlF-NOTA-cysVar3 eluted 
between 12 and 15 min; 
18
F-AlF-NOTA-cysVar7 eluted between 12 and 14 min). 
While the HPLC analysis was being performed, the remainder of the reaction mixture 
was separated using a pretreated Oasis HLB Plus Light or C18 Sep-Pak Light 
cartridge (Waters, Milford, MA) eluting first with water (5 mL) to remove any 
unbound 
18
F species and then ethanol (0.1 mL fractions for 4 fractions and then 0.6 
mL). The 
18
F-AlF-NOTA-pHLIP derivatives eluted within the first three fractions in 
ethanol. The ethanolic solution was diluted with sterile PBS to provide < 10 % ethanol 
in the solution before HPLC analysis (Jupiter C-18, 5 μm, 300 Å, 250 × 4.6 mm, 
Phenomenex; 5-95 % AcN in water with 0.1 % TFA over 15 min at 1 mL/min). The 
radiochemical purity of the species was always ≥ 95% and the specific activity (using 
the original amount of peptide added to the reaction mixture) was estimated to be 
79.9-178.1 μCi/μmol (2.96-6.60 GBq/μmol). The reaction yielded 6.02-9.24 mCi 
(223-342 MBq) with an overall, decay-corrected (to beginning of labeling procedure) 
isolated yield of 2.33-48.6 %. 
 
Nonradioactive standards  
General labeling methods for Cu-NOTA-pHLIP. Approximately 200 μL of 36.4 M 
Cu(OAc)2 in 0.1 M NH4OAc (pH ~5) in metal-free water was added to 5-6 mg of 
peptide in approximately 200 μL of DMSO. The mixtures were reacted in a 
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thermomixer at 50 °C for 1 h, and then filtered through a 0.2 μm filter. The filter was 
washed with an additional 1 mL of 50% AcN in water and 2 mL of water, 
sequentially. The combined filtrate was HPLC purified (10-95% AcN in water over 30 
min with a Jupiter C-18 column, 5 μm, 300 Å, 250 × 4.6 mm, Phenomenex). The 
collected fraction (14.5-15.5 min for Cu-NOTA-WT, 13.9-15 min for Cu-NOTA-
Var3, 13.2-14.1 min for Cu-NOTA-Var7, 12.2-13.5 min for Cu-NO2A-cysWT, 13-
15.3 min for Cu-NO2A-cysVar3, and 12.5-16 min Cu-NO2A-cysVar7) was 
lyophilized.  
General labeling methods for AlF-NOTA-pHLIP. Sodium fluoride (19.8 mg, 0.47 
mmol) was dissolved in 150 μL of 0.1 M NH4OAc in metal-free water (pH ~ 4.1). The 
resulting solution was added to 13.7 mg AlCl3 (0.057 mmol) with 50 μL of 0.1 M 
NH4OAc buffer (pH ~ 4.1). The AlF3 solution (60 μL) was added to approximately 7 
mg of peptide dissolved in 60 μL of EtOH. The reaction mixtures were reacted at 50 
°C on a thermomixer for 1 h before being HPLC purified (10-95% AcN in water over 
30 min with a Jupiter column, 5 μm, 300 Å, 250 × 4.6 mm, Phenomenex). The 
collected fraction (14.7-16.5 min for AlF-NOTA-WT, 13.8-15.4 min for AlF-NOTA-
Var3, 13-14.6 min for AlF-NOTA-Var7, 12.5-17.5 min for AlF-NO2A-cysWT and 
AlF-NO2A-cysVar3, and 12-16 min AlF-NO2A-cysVar7) was lyophilized. 
 
Cell culture methods and in vivo models  
4T1 cell culture. The 4T1 cells, derived from spontaneous breast tumor in a BALB/c 
mouse, were provided by Fred Miller (Karmanos Cancer Institute, Detroit, MI) and 
cultured in Dulbecco’s modified Eagle’s high glucose media with 10 % FCS, 2 mM L-
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glutamine, penicillin, and streptomycin or from ATCC (Manassas, VA) and cultured 
in RPMI-1640 medium modified to contain 2 mM L-glutamine, 10 mM HEPES, 1 
mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L NaHCO3, penicillin, and 
streptomycin.  
4T1 orthotopic BALB/c mouse model. The cells were removed from the flasks, 
concentrated, and resuspended in minimal media for cell counting. The cells were then 
diluted to contain approximately 1 million cells in 30 μL of media (for orthotopic 
allografts). Following an MSKCC Institutional Animal Care and Use Committee 
approved protocol, 8-10-week-old BALB/c mice (Charles River Laboratories, 
Wilmington, MA) were surgically implanted with one million 4T1 cancer cells into 
the first or the last mammary fat pad of the right side of the animal using aseptic 
surgical techniques and sterile staple closures while the mice were under anesthetic. 
Additionally, mice were given injections of meloxicam (24 h pain killer) in the scruff 
and bupivacaine intradermally prior to surgical incisions. One day post-surgery, the 
mice were again given meloxicam and checked to ensure that the closure was healing. 
Two and three days post-surgery, the mice were checked to ensure that the animals 
were healthy and recovering well from the surgery. Five to seven days post-surgery, 
the staples were removed. Five to nine days post-surgery, the mice were injected with 
50-75 μCi (0.9-0.4 nmol) of the respective radiopharmaceutical for in vivo 
biodistribution or 500-600 μCi (9-11 nmol) for in vivo imaging. The mice receiving 
64
Cu-NOTA-pHLIP were sacrificed at 1, 2, 4, 12, 24, 36, and 48 h; the mice receiving 
18
F-AlF-NOTA-pHLIP were sacrificed at 0.5, 1, 2, 4, 6 and 8 h.  
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PC3 cell culture. The PC3 cells, prostate cancer derived from a human bone 
metastasis, were purchased from ATCC (Manassas, VA) and cultured in F-12K 
Medium (Kaighn's Modification of Ham's F-12 Medium) with, 10% FCS, 2 mM L-
glutamine, 1.5 g/L NaHCO3, penicillin, and streptomycin. 
PC3 shoulder nude mouse xenografts. The cells were removed from the flasks, 
concentrated, and resuspended in minimal media for cell counting. The cells were then 
diluted to contain approximately 3 million cells in 150 μL of 1:1 media and matrigel 
(for shoulder xenografts). Following an MSKCC Institutional Animal Care and Use 
Committee approved protocol, 150 μL of the cell suspension was injected 
subcutaneously in 6-9-week-old nude male mice (CRL). Mice were used in studies at 
3 weeks post inoculation. The mice were injected with 50-75 μCi (0.9-0.4 nmol) of the 
respective radiopharmaceutical for in vivo biodistribution or 500-600 μCi (9-11 nmol) 
for in vivo imaging. The mice receiving 
64
Cu-NOTA-cysVar3 were sacrificed at 1, 4, 
12, 24, and 48 h; the mice receiving 
18
F-AlF-NOTA-cysVar3 were sacrificed at 1, 4, 6 
and 8 h.  
LNCaP cell culture. The LNCaP cells, prostate cancer derived from a human 
supraclavicular lymph node metastasis, were purchased from ATCC (Manassas, VA) 
and cultured in RPMI-1640 medium modified to contain 2 mM L-glutamine, 10 mM 
HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L NaHCO3, penicillin, and 
streptomycin.  
LNCaP shoulder nude mouse xenografts. The cells were removed from the flasks, 
concentrated, and resuspended in minimal media for cell counting. The cells were then 
diluted to contain approximately 3-6 million cells in 150 μL of 1:1 media and matrigel 
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(or shoulder xenografts). Following an MSKCC Institutional Animal Care and Use 
Committee approved protocol, 150 μL of the cell suspension was injected 
subcutaneously in 6-8-week-old nude male mice (CRL). Mice were used in studies at 
3-8 weeks post inoculation. The mice were injected with 50-75 μCi (0.9-0.4 nmol) of 
the respective radiopharmaceutical for in vivo biodistribution or 500-600 μCi (9-11 
nmol) for in vivo imaging. The mice receiving 
64
Cu-NOTA-cysVar3 were sacrificed at 
1, 4, 12, 24, and 48 h; the mice receiving 
18
F-AlF-NOTA-cysVar3 were sacrificed at 1, 
4, 6 and 8 h.  
B16-F10 cell culture. The B16-F10 cells, derived from spontaneous melanoma in a 
C57Bl/6 mouse, were purchased from ATCC (Manassas, VA) and cultured in 
Dubelco’s modified Eagle’s high glucose media with 10 % FCS, 4 mM L-glutamine, 1 
mM sodium pyruvate, 1.5 g/L NaHCO3, penicillin, and streptomycin.  
Orthotopic B16-F10 shoulder allografts. The cells were removed from the flasks, 
concentrated, and resuspended in minimal media for cell counting. The cells were then 
diluted to contain approximately 100,000 cells in 100 μL of media (for shoulder 
allografts). Following an MSKCC Institutional Animal Care and Use Committee 
approved protocol, C57Bl/6 female mice (CRL) and BALB/c female mice (CRL) were 
injected with 100 μL of the cell suspension intradermally as per a media substituted 
protocol from Overwijk & Restifo (Current Protocols in Immunology, 2000: 20.1.1-
20.1.29). The mice were used in studies at approximately 9-14 days post inoculation. 
The mice were injected with 50-75 μCi (0.9-0.4 nmol) of the respective 
radiopharmaceutical for in vivo biodistribution or 500-600 μCi (9-11 nmol) for in vivo 
imaging. The mice receiving 
64
Cu-NOTA-cysVar3 were sacrificed at 1, 4, 12, 14.5, 
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and 24 h; the mice receiving 
18
F-AlF-NOTA-cysVar3 were sacrificed at 1, 4, 6 and 8 
h.  
U-87 MG cell culture. The human glioblastoma cell line, U-87 MG, was purchased 
from American Type Culture Collection (ATCC, Manassas, VA) and cultured in 
Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum, 2mM L-
Glutamine, 1500mg/L Sodium Bicarbonate, 100 units/mL penicillin G and 100 μg/mL 
streptomycin (prepared by the MSKCC Media Preparation Core). 
U-87 MG shoulder xenografts. The cells were removed from the flasks, concentrated, 
and resuspended in minimal media for cell counting. The cells were then diluted to 
contain approximately 1 million cells in 150 μL of 1:1 media and matrigel (or 
shoulder xenografts). Following an MSKCC Institutional Animal Care and Use 
Committee approved protocol, 150 μL of the cell suspension was injected 
subcutaneously in 12-week-old nude male mice (CRL). Mice were used in studies at 
2-3 weeks post inoculation. The mice were injected with 400-500 μCi (7-10 nmol) for 
in vivo imaging. The mice were sacrificed at 6 h after imaging (n=6). 
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SUPPORTING INFORMATION FIGURES 
 
Figure S1. PET Maximum intensity projection (MIP) showing differences in the 
tracer distribution at 4 h p.i. for all 12 tracers (A) and the PET imaging slices at 15 
%ID/g at 4 h p.i. for the 
18
F-AlF-cyspHLIP constructs (V) in BALB/c female mice 
bearing 4T1 tumor allografts. The yellow arrowheads indicate where the tumor is 
located in the mouse. The MIPs correspond to the same images shown in Figure 3. 
The slices are the same as those shown in Figure 3, just at 15 %ID/g. Only ex vivo 
biodistribution data was obtained for 
64
Cu-NOTA-Var7.  
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Figure S2. Three states of NO2A-cysVar3 and NOTA-Var3 constructs. The 
constructs were examined under varying conditions for the presence of the three states 
of pHLIP® peptide: State I is the construct in solution at pH 8 (black lines), State II is 
the construct in the presence of POPC liposomes at pH 8 (blue lines), and State III is 
the construct folded and inserted in the lipid membrane when the pH is dropped from 
pH 8 to pH 4 by the addition of an aliquot of HCl (red lines). The concentrations of 
construct and lipids were 5 μM and 1 mM, respectively. 
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Figure S3. State II and State III of NO2A-cyspHLIP constructs. The constructs were 
examined in the presence of liposomes under varying pH levels: State II is the 
construct in the presence of POPC liposomes at pH 8 (blue lines), State III is the 
construct folded and inserted in the lipid membrane when the pH is dropped from pH 
8 to pH 4 by the addition of an aliquot of HCl (red lines). The concentrations of 
construct and lipids were 5 μM and 1 mM, respectively, with physiological levels of 
free magnesium and calcium ions (0.65 mM and 1.25 mM, respectively).  
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Figure S4. pH dependent bilayer insertion of constructs. Changes in intrinsic construct 
fluorescence are used to measure the insertion of the construct population as a function 
of pH (transition from State II, at high pH, to State III, at low pH). Amount of 
construct population in State II is measured on the y-axis. The red and blue lines are 
fitting curves and 95% confidence intervals, respectively. These experiments were 
carried out with physiological levels of free magnesium and calcium ions (0.65 mM 
and 1.25 mM, respectively).  
 
  
 
 
87 
 
Figure S5. Initial results from brain tumor uptake study. Images of the uptake of 
U87MG tumors xenografted in the skull (U87MG*) or flank (U87MG) on male nude 
mice and GSC 5-22 tumors orthotopically xenografted behind an intact BBB in IRC-
SCID male mice at 4 h post injection (A). The U87MG* tumors did not infiltrate the 
brain and only the portion of the tumor that was in the skull bone and protruding from 
the skull showed uptake. The construct biodistribution of six male nude mice with 
flank U87MG xenografted tumors (B). The yellow arrowheads in (A) indicate where 
the tumor is located in the mouse.  
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Figure S6. Relative autoradiography of tumor slices from text Figure 6. The slices 
show the overall difference in uptake of the tracer at 24 h p.i. Both of the slices were 
on the same autoradiography plate and, therefore, are relative to each other.  
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Figure S7. Comparison of tumor uptake to previously reported studies for A) PC3 and 
B) LNCaP tumor bearing nude male mice at 1, 4, and 24 h with ex vivo biodistribution 
and in vivo imaging values. For imaging time points, ROIs were drawn on the coronal, 
sagittal, and transverse slices and the middle median value was tabulated for each 
mouse, the average of the four mice are shown with the standard deviation. Values 
from previous studies were used as reported. 
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Figure S8. Comparison of tumor:tissue ratios at 4 h and 24 h to previous studies: A) 
PC3 at 4 h; B) PC3 at 24 h; C) LNCaP at 4 and 24 h. 
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SUPPORTING INFORMATION TABLES  
 
Table S1. General specific activities of tracers produced for this study. 
a
Approximated 
from the amount of total peptide added. 
b
Calculated from the UV/vis standard 
concentration curve. 
cIn a separate experiment, a specific activity of 1656 μCi/nmol 
was attained, but the lower specific activity material was used in the studies in order to 
be comparable throughout. 
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DATA FOR EACH TRACER FROM THIS STUDY IN FEMALE, BALB/C 
MICE WITH ORTHOTOPIC 4T1 BREAST CANCER ALLOGRAFTS 
64
Cu-NOTA-WT 
 
Table S1-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NOTA-WT administered via the 
lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer allografts 
implanted into the mammary fat pad. 
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Table S1-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NOTA-WT administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S1-1. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NOTA-WT (n = 4 (3 at 24 h)) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
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Fig. S1-2. HPLC Chromatogram of the Reconstituted 
64
Cu-NOTA-WT Injectate 
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64
Cu-NOTA-Var3 
 
Table S2-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NOTA-var3 administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S2-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NOTA-Var3 administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S2-1. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NOTA-Var3 (n = 5 (4 at 4 h)) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
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Fig. S2-2. HPLC Chromatogram of the Reconstituted 
64
Cu-NOTA-Var3 Injectate 
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64
Cu-NOTA-Var7 
 
Table S3-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NOTA-var7 administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S3-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NOTA-Var7 administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
  
  
 
 
102 
 
Fig. S3-1. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NOTA-var7 (n = 4) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
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Fig. S3-2. HPLC Chromatogram of the Reconstituted 
64
Cu-NOTA-Var7 Injectate 
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18
F-AlF-NOTA-WT 
 
Table S4-1. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NOTA-WT administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S4-2. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NOTA-WT administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S4-1. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NOTA-WT (n = 5) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
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Fig. S4-2. HPLC Chromatogram of the Reconstituted 
18
F-AlF-NOTA-WT Injectate 
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18
F-AlF-NOTA-Var3 
 
Table S5-1. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NOTA-Var3 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S5-2. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NOTA-Var3 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S5-1. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NOTA-Var3 (n = 5 (4 at 4 
h)) administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
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Fig. S5-2. HPLC Chromatogram of the Reconstituted 
18
F-AlF-NOTA-Var3 Injectate 
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18
F-AlF-NOTA-Var7 
 
Table S6-1. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NOTA-Var7 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S6-2. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NOTA-Var7 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S6-1. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NOTA-Var7 (n = 5) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
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Fig. S6-2. HPLC Chromatogram of the Reconstituted 
18
F-AlF-NOTA-Var7 Injectate 
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64
Cu-NO2A-cysWT 
 
Table S7-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NO2A-cysWT administered via 
the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S7-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysWT administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S7-1. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysWT (n = 3-5) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
Glucose was administered i.p. 30 min prior to tracer injection. 
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Fig. S7-2. HPLC Chromatogram of the Reconstituted 
64
Cu-NO2A-cysWT Injectate 
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64
Cu-NO2A-cysVar7 
 
Table S8-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NO2A-cysVar7 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S8-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar7 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S8-1. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar7 (n = 4-5) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
Glucose was administered i.p. 30 min prior to tracer injection. 
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Fig. S8-2. HPLC Chromatogram of the Reconstituted 
64
Cu-NO2A-cysVar7 Injectate 
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18
F-AlF-NO2A-cysWT 
 
Table S9-1. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysWT administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
  
  
 
 
125 
 
Table S9-2. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysWT 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad. 
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Fig. S9-1. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysWT (n = 4) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
Glucose was administered i.p. 30 min prior to tracer injection. 
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Fig. S9-2. HPLC Chromatogram of the Reconstituted 
18
F-AlF-NO2A-cysWT Injectate 
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18
F-AlF-NO2A-cysVar7 
 
Table S10-1. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysVar7 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad. 
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Table S10-2. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar7 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad. 
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Fig. S10-1. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar7 (n = 3-5) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
Glucose was administered i.p. 30 min prior to tracer injection. 
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Fig. S10-2. HPLC Chromatogram of the Reconstituted 
18
F-AlF-NO2A-cysVar7 
Injectate 
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64
Cu –NO2A-cysVar3 
 
Table S11-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Table S11-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 breast cancer 
allografts implanted into the mammary fat pad. 
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Fig. S11-1. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar3 (n = 3-8) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
Glucose was administered i.p. 30 min prior to tracer injection. 
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Fig. S11-2. HPLC Chromatogram of the Reconstituted 
64
Cu –NO2A-cysVar3 Injectate 
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18
F-AlF-NO2A-cysVar3 
 
Table S12-1. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad. 
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Table S12-2. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad. 
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Fig. S12-1. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar3 (n = 4-10) 
administered via the lateral tail vein in female, BALB/c mice with orthotopic 4T1 
breast cancer allografts implanted into the mammary fat pad full graph from text. 
Glucose was administered i.p. 30 min prior to tracer injection. 
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Fig. S12-2. HPLC Chromatogram of the Reconstituted 
18
F-AlF-NO2A-cysVar3 
Injectate 
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DATA FROM LEAD TRACERS IN OTHER TUMOR MODELS 
64
Cu-NO2A-cysVar3 in PC3 tumor-bearing male nude mice 
 
Table S13-1. Tissue uptake (mean %ID ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in male, nude mice with shoulder PC3 (prostate cancer) 
xenografts. 
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Table S13-2. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in male, nude mice with shoulder PC3 (prostate cancer) 
xenografts. 
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64
Cu-NO2A-cysVar3 in LNCaP tumor-bearing male nude mice 
 
Table S13-3. Tissue uptake (mean %ID ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in male, nude mice with shoulder LNCaP (prostate cancer) 
xenografts. 
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Table S13-4. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in male, nude mice with shoulder LNCaP (prostate cancer) 
xenografts. 
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64
Cu-NO2A-cysVar3 in B16-F10 tumor-bearing female C57Bl/6 mice 
 
Table S13-5. Tissue uptake (mean %ID ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10 (melanoma) 
allografts. 
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Table S13-6. Tissue uptake (mean %ID/g ± SD) of 
64
Cu-NO2A-cysVar3 administered 
via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10 (melanoma) 
allografts. 
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18
F-AlF-NO2A-cysVar3 in PC3 tumor-bearing male nude mice 
 
Table S13-7. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in male, nude mice with shoulder PC3 (prostate 
cancer) xenografts. 
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Table S13-8. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in male, nude mice with shoulder PC3 (prostate 
cancer) xenografts. 
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18
F-AlF-NO2A-cysVar3 in LNCaP tumor-bearing male nude mice 
 
Table S13-9. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in male, nude mice with shoulder LNCaP 
(prostate cancer) xenografts. 
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Table S13-10. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in male, nude mice with shoulder LNCaP 
(prostate cancer) xenografts. 
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18
F-AlF-NO2A-cysVar3 in B16-F10 tumor-bearing female C57Bl/6 mice 
 
Table S13-11. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10 
(melanoma) allografts and one group of female, BALB/c mice with orthotopic B16-
F10 (melanoma) allografts at 6 h. *BALB/c time point. 
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Table S13-12. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in female, C57Bl/6 mice with orthotopic B16-F10 
(melanoma) allografts and one group of female, BALB/c mice with orthotopic B16-
F10 (melanoma) allografts at 6 h. *BALB/c time point. 
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18
F-AlF-NO2A-cysVar3 in U87MG tumor-bearing male nude mice 
 
Table S13-13. Tissue uptake (mean %ID ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in male, nude mice with U87MG xenografted 
flank tumors at 6 h. *BALB/c time point. 
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Table S13-14. Tissue uptake (mean %ID/g ± SD) of 
18
F-AlF-NO2A-cysVar3 
administered via the lateral tail vein in male, nude mice with U87MG xenografted 
flank tumors at 6 h. *BALB/c time point. 
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Significance Statement 
Two aspects of contemporary cancer chemotherapy are targeted therapy and targeted 
delivery. While there are many examples of targeted therapy, targeted delivery has 
been limited due to its reliance on tumor cell biomarkers, either in the form of antigens 
or of specific binding sites; because of the dependence on the presence of these 
suitable biomarkers and because of high tumor heterogeneity, targeted delivery has not 
shown great success so far. The emergence of pHLIP technology provides an 
alternative by targeting a metabolic marker: tumor cell surface acidity. While 
promising, the technology is still developing and advances could have a significant 
impact on therapy. Here, we report several new pHLIPs, including pHLIP bundles, a 
new concept, and we thoroughly evaluate these constructs alongside a new generation 
of pHLIPs. We also discuss challenges inherent to the design and accurate evaluation 
of pHLIPs. Our research elucidates the strengths and weaknesses of existing pHLIPs, 
proposes future peptide modifications that could further improve tumor targeting, and 
discusses the applicability of this new generation of pHLIPs for specific areas of drug 
delivery. These principles and new constructs promise increasing success in tumor 
therapy. 
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Abstract 
pH (Low) Insertion Peptides (pHLIPs) target acidity at the surfaces of cancer cells and 
show utility in a wide range of applications including tumor imaging and the 
intracellular delivery of therapeutic agents. Here we report new pHLIP constructs that 
significantly improve the targeted delivery of agents into tumor cells. The new 
constructs include pHLIP bundles (conjugates consisting of two or four pHLIP 
peptides linked by polyethelyne glycol) and Var3 pHLIPs containing either the non-
standard amino acid γ-carboxyglutamic acid or a glycine-leucine-leucine motif. The 
performance of the new constructs in vitro and in vivo was compared with previous 
pHLIP variants. A wide range of experiments was performed on nine constructs 
including: i) biophysical measurements using steady-state and kinetic fluorescence 
spectroscopy, circular dichroism (CD) spectroscopy, and oriented circular dichroism 
(OCD) spectroscopy to study the pH-dependent insertion of pHLIP variants across the 
membrane lipid bilayer; ii) cell viability assays to gauge the pH-dependent potency of 
peptide-toxin constructs by assessing the intracellular delivery of the polar, cell-
impermeable cargo molecule amanitin at physiological and low pH (pH 7.4 and 6.0, 
respectively); and iii) tumor targeting and biodistribution measurements using 
fluorophore-peptide conjugates in a breast cancer mouse model. The main principles 
of the design of pHLIP variants for a range of medical applications are discussed. 
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Introduction 
The targeted delivery of drugs to cancer cells promises to maximize their therapeutic 
effects while reducing side effects. Although many biomarkers exist that can be 
exploited to improve tumor targeting and treatment outcomes, such as various 
receptors overexpressed at the surfaces of some cancer cells, useful markers are not 
present in all tumors. Further, the heterogeneity of the cancer cell population in an 
individual tumor and between tumors of various patients limits the effective use of 
biomarker targeting technologies, and rapid mutation increases the likelihood of the 
selection of cancer cell phenotypes that do not express high levels of the targeted 
biomarker. Thus, biomarker targeting can act as a selection method that may lead to 
the development of drug resistance and poor patient outcomes (1-3). 
 It is well known that acidosis is ubiquitous in tumors, including both primary 
tumors and metastases, as a consequence of their rapid metabolism (4). The acidic 
microenvironment is generated by the increased use of glycolysis by cancer cells, and 
by the abundance of carbonic anhydrase proteins on the cancer cell surfaces. Tumor 
cells stabilize their cytoplasmic pH by exporting the acidity to the extracellular 
environment. As a result of the proton flux and resulting membrane potential, the 
extracellular pH is lowest at the surfaces of cancer cells, where it is significantly lower 
than both the normal physiological pH and the bulk extracellular pH in tumors (5-7). 
The low pH region persists at the cancer cell surface even in well-perfused tumor 
areas. The acidity on the surfaces of cancer cells is a targetable characteristic that is 
not subject to clonal selection, and the level of acidity is a predictor of tumor invasion 
and aggression since more rapidly growing tumor cells are more acidic. 
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 The emerging technology based on pH (low) insertion peptides (pHLIPs) 
comprises a variety of acidity-targeting peptides, each possessing different tumor-
targeting characteristics. pHLIPs can be used in a wide variety of applications, so it is 
desirable to have a range of options available for use in specific applications. Some 
examples of these applications include: i) fluorescence imaging (8-10) and 
fluorescence image-guided surgery (11); ii) nuclear imaging, including positron 
emission tomography (PET) and single-photon emission computed tomography 
(SPECT) (12, 13); iii) therapy, including the targeted delivery of polar toxins that 
cannot cross cell membranes (14, 15), drug-like molecules that inherently diffuse 
across cell membranes (16, 17), and gene therapy (18); and iv) nanotechnology, in 
which pHLIP is used to enhance the delivery of gold nanoparticles (19, 20) or 
liposome-encapsulated payloads to cancer cells (21). 
 pHLIPs are triggered to insert across the membranes of cancer cells by the 
acidity at the cancer cell surface. The behavior of peptides in the pHLIP family is 
typically described in terms of three states: at physiological pH (pH 7.4), peptides 
exist in equilibrium between a solvated state (State I) and a membrane-adsorbed state 
(State II); a decrease in pH shifts the equilibrium toward a membrane-inserted state 
(State III) (22). The mechanism of action of peptides in the pHLIP family is well 
understood: protonatable residues, which are interspersed throughout the hydrophobic 
middle region and the C-terminal, membrane-inserting region of the peptides, are 
negatively charged at physiological pH but become neutralized by protonation with a 
decrease in pH. The loss of charge and increase in overall hydrophobicity drives 
pHLIPs to partition across the hydrophobic core of the membrane bilayer to form a 
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transmembrane helix. This helix spans the lipid bilayer, leaving the N-terminus in the 
extracellular space and placing the C-terminus in the intracellular space where, due to 
the more alkaline pH in the cytosol, the C-terminus can again become deprotonated 
and charged, stably anchoring the peptide in the cell membrane. 
 Following an extensive characterization of wild-type (WT) pHLIP, a first-
generation of pHLIP variants was created to examine the effects on targeting due to 
fairly straightforward changes to the WT primary structure such as sequence 
truncation, the addition and replacement of some protonatable residues with others, 
and sequence reversal (23-25). Importantly, a number of the changes that were 
investigated had adverse effects on pHLIP properties, suggesting that further studies 
might reveal design principles and give more useful molecules for targeted therapy. Of 
these first-generation variants, Variant 3 (Var3) appeared to have the most desirable 
insertion characteristics and much research has been focused on the use of Var3 for 
various applications (10, 11, 26, 27). 
 Lately, new variants have emerged that incorporate more innovative changes to 
the peptide primary structure; these changes include the use of the non-standard amino 
acids γ-carboxyglutamic acid (Gla), a residue with two protonatable carboxyl groups, 
and α-aminoadipic acid (Aad), a more hydrophobic version of the glutamic acid 
residue (28), as well as the creation of a pHLIP peptide de novo, ATRAM (29). Here, 
we examine several new members of the pHLIP family of peptides, including pHLIP 
bundles, compare their biophysical properties to some of the previous generation 
variants, and evaluate the utility of nine pHLIPs in drug delivery and tumor imaging 
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applications. These variants significantly expand the useful range of applications in 
targeted cancer therapy. 
 
Results 
pHLIP constructs. We have designed two new pHLIP variants, Var3/Gla 
(incorporating the non-standard amino acid Gla) and Var3/GLL (utilizing a glycine-
leucine-leucine motif), and a novel construct: pHLIP bundles. pHLIP bundles consist 
of two- or four-armed 2 kDa polyethylene glycol (PEG) spacers conjugated to the 
cysteine residue at the N-terminus of WT: PEG-2WT (Figure 1a) and PEG-4WT 
(Figure 1b), respectively. Our motivation is to increase both the membrane affinity 
and the cooperativity of the transition from the membrane-surface state to the 
membrane-inserted state. Enhancement of affinity is expected to improve targeting, 
and higher cooperativity should narrow the pH window that produces transmembrane 
drug delivery. The nine pHLIP variants studied (molecular weights and retention times 
are provided in Table S2) were as follows, with additional variations from the addition 
of single N- or C-terminal cysteine or lysine residues for conjugation purposes (a list 
of all peptides investigated is provided in Table S1): 
 
WT:   AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT 
PEG-2WT:  Two-arm PEG conjugated to two WT pHLIPs 
PEG-4WT:  Four-arm PEG conjugated to four WT pHLIPs 
WT/Gla:  AEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADEGT 
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WT/Gla/Aad:  AEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADEGT 
Var3:   ADDQNPWRAYLDLLFPTDTLLLDLLW 
Var3/Gla:  ADDQNPWRAYLGlaLLFPTDTLLLDLLW 
Var3/GLL:   GEEQNPWLGAYLDLLFPLELLGLLELGLWG 
ATRAM:  GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN 
 
 These pHLIP variants can be grouped together in various ways by shared 
characteristics. A WT-like group contains peptides with two protonatable residues 
(shown in bold) in the underlined putative transmembrane (TM) region, multiple 
protonatable residues in the membrane-inserting C-terminal region, and two 
tryptophan residues (residue W) located at the beginning of the helix-forming TM 
region; this group includes WT, PEG-2WT and PEG-4WT, WT/Gla, and 
WT/Gla/Aad. A Var3-like group is based on Var3 from the first generation of pHLIP 
variants (25). This group includes Var3, Var3/Gla and Var3/GLL, each of which have 
three protonatable residues in the TM region and tryptophan residues located at the 
beginning and end of the TM region. Considering this scheme, ATRAM, with its 
multiple glycine and leucine residues and single tryptophan located about two-thirds 
of the way through its TM region, is in a group of its own. Other subgroups can be 
considered as well: a subgroup of peptides that incorporate the non-standard Gla 
residue, shown in italics (i.e., WT/Gla, WT/Gla/Aad, and Var3/Gla), and another 
subgroup that includes peptides containing the GLL motif (Var3/GLL and ATRAM). 
 When performing analysis of biophysical measurements, analyzing variants 
with respect to their group-mates becomes important: the very different characteristics 
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of peptides from various groups make it difficult to accurately compare the behavior 
of all peptides at the same time. 
 
Biophysical steady-state and kinetics studies. A variety of spectroscopic techniques 
were employed to probe the interaction between pHLIP variants and POPC 
phospholipid bilayers in liposomes; these techniques included steady-state 
fluorescence spectroscopy, circular dichroism (CD) spectroscopy, oriented circular 
dichroism (OCD) spectroscopy, and stopped-flow fluorescence measurements. Steady-
state fluorescence and CD experiments were conducted in phosphate buffer titrated 
with hydrochloric acid to drop the pH from pH 8 to pH 4 to ensure consistency with 
previously published data (25, 29, 30). Steady-state and kinetics fluorescence 
experiments measuring the pH-dependent transition from State II to State III were 
carried out in phosphate buffer containing physiological concentrations of calcium 
(1.25 mM) and magnesium (0.65 mM) ions (the concentrations at which free calcium 
and magnesium ions are found in the blood), since we conjectured that some of the 
studied constructs might interact with these ions, and that this interaction might 
significantly affect the ultimate in vivo performance of the peptides. 
We established that, in solution, PEG-2WT and PEG-4WT most probably exist 
in compact coil conformations, where tryptophan and other aromatic residues can 
form stacking structures. The resulting exciton formation was seen as a minimum 
around 230 nm in the CD spectra of these pHLIP bundles (Figure 1e and 1f). At pH 8, 
changes in tryptophan fluorescence show that both constructs interact with the lipid 
bilayer and it appears that PEG-4WT exhibits stronger binding than PEG-2WT in 
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State II. With a reduction of pH, both pHLIP bundles inserted into the bilayer to form 
helices, and the transmembrane orientations of these helices were confirmed by OCD 
measurements (Figure 1g and 1h). It is important to note that in State III, the 
membrane-inserted state, the exciton signal generated by π-π stacking is no longer 
present, suggesting that the insertion of each pHLIP renders it independent of the 
other(s). The apparent pK of the transition from State II to State III was shifted to pH 
6.6 and, as might be expected, the cooperativity of the transition was increased for 
PEG-4WT compared to PEG-2WT (Figure 1i and 1j). 
We compared the groups consisting of WT, Var3, and ATRAM pHLIP 
variants to the newly designed Var3/Gla and Var3/GLL pHLIP variants. The retention 
times of the peptides indicate increasing hydrophobicity within the groups in the 
following order, from less to more hydrophobic: WT, WT/Gla, WT/Gla/Aad and 
Var3, Var/Gla, Var3/GLL, and ATRAM, with ATRAM being the most hydrophobic 
(Table S2). Both new pHLIP variants, Var3/Gla and Var3/GLL, demonstrated a pH-
dependent interaction with the membrane (Figure S1). Var3/GLL showed a higher 
percentage of membrane-inserted population at pH 8, which reflects a higher affinity 
of the peptide for the lipid bilayer both at physiological and high pH due to the 
increased hydrophobicity of the peptide.  
As seen for previous pHLIP designs, a blue shift (or decrease in Stokes shift) 
resulting from the environmental changes from State I to State II and State III was 
observed for all peptides (Table S3), indicating partitioning of the peptides into the 
lipid bilayer. However, we cannot directly compare the positions of fluorescence 
spectra maxima for peptides belonging to the different groups, since the locations of 
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the tryptophan residues within the peptides varies greatly. With this fact in mind, we 
can conclude that the peptides had very different conformations in State II at pH 8, 
and that the highest membrane affinity was exhibited by the PEG-pHLIPs and by the 
WT/Gla/Aad, Var3/GLL, and ATRAM peptides. The PEG-pHLIPs have multiple 
binding sites due to the linking of multiple WT peptides within a single construct, 
which is expected to enhance binding affinity. The WT/Gla/Aad, Var3/GLL, and 
ATRAM have the most hydrophobic sequences, and thus exhibit strong 
binding/insertion. We also found that some peptides were especially sensitive to the 
presence of calcium and magnesium ions, namely WT, variants containing the Gla 
residue (WT/Gla, WT/Gla/Aad, and Var3/Gla) and ATRAM. This sensitivity was 
most obviously seen as a decreased Stokes shift (usually 2-3 nm) in State I and/or 
State II, and might reflect slight increases in the hydrophobicity of the peptides caused 
by the coordination of divalent cations resulting from the presence of closely spaced 
protonatable residues, such as those found in the C-terminal region of WT and, to 
some degree, in ATRAM, or to the presence of the Gla residue, with its two 
protonatable carboxyl groups, in the WT/Gla, WT/Gla/Aad, and Var3/Gla peptides. It 
is known that a Gla residue can form a complex with a calcium ion (31-33). The 
decrease in Stokes shift in State II is likely due to the location of membrane-adsorbed 
peptides deeper in the lipid membrane (especially for the more hydrophobic pHLIPs: 
WT/Gla/Aad, Var3/GLL, and ATRAM) and/or a shift in peptide population from the 
solvated to the membrane-adsorbed state. 
In contrast to tryptophan fluorescence changes, which are dependent on the 
location of tryptophan residues within the peptide sequence, the appearance of helicity 
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is a more general parameter which can be compared among all peptides. In Figure 2a 
(and Table S3), we give the ratio of ellipticity at 205 nm to 222 nm, an indicator of the 
degree of helicity (lower ratios indicate higher helicity), obtained for different peptides 
in different states. In State I, the lowest ratios were observed for pHLIP bundles, 
which correlate with the appearance of the exciton signal at 230 nm. In State II, the 
least unstructured peptides (ratio <1.5) were PEG-4WT, WT/Gla/Aad, Var3/GLL, 
ATRAM, and PEG-2WT, which exhibited a higher affinity to the membrane and an 
increase in the peptide-inserted population at pH 8. At low pH, all peptides exhibited 
similar helical content, as expected from the observed formation of TM helices.  
 The transitions from State II to State III seen in steady-state and kinetics modes 
exhibited pK values in the range of pH 5.7 to 6.6 in the presence of physiological 
concentrations of calcium and magnesium ions, with the highest cooperativity 
observed for PEG-4WT, and transition times varying from 0.1 to 37.5 s (Table 1). 
There are subtleties that affect the comparison and interpretation of the data: i) the 
peptides are in different starting conditions in State II at pH 8 due to greatly differing 
overall peptide hydrophobicity; ii) pK values and characteristic times report the 
movement of tryptophan residues into environments inside the membrane; however, 
since the tryptophan residues are located in different regions of each pHLIP, their 
propagation into the membrane as measured via changes in fluorescence parameters 
should be expected to be different; and iii) the cooperativity of the transition is a 
somewhat unstable parameter in the fitting of experimental pH-dependence data using 
the Henderson-Hasselbalch equation, especially if slopes are introduced at the 
initiation and completion of the transition (34). Low values of cooperativity (n <1) 
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were observed for the peptides with tryptophan residues located at (Var3 group) or 
close (ATRAM) to the C-terminus, which must be translocated across the cell 
membrane. ATRAM and Var3/GLL, which are the most hydrophobic pHLIPs and are 
therefore likely to be located more deeply than others in the membrane at pH 8, 
demonstrated the fastest times of insertion. As we showed previously, the removal of 
protonatable residues from the inserting C-terminus increases the rate of the transition 
from State II to State III (24, 25). Thus, the group of Var3-like peptides exhibited fast 
insertion times (t <1 s). In the group of WT peptides, the time of insertion decreased as 
the hydrophobicity of the peptide increased, with insertion times listed in the 
following order (from longest to shortest time of insertion): WT, WT/Gla, 
WT/Gla/Aad, PEG-2WT, and PEG-4WT. 
 
Intracellular delivery of polar cargo. Before studying the toxicity of pHLIP-toxin 
conjugates, we investigated whether the pHLIP bundles could cause any acute 
cytotoxicity by themselves. HeLa cells were treated with either PEG-2WT or PEG-
4WT at physiological pH (pH 7.4) and low pH (pH 6.0) for two hours. We did not 
observe any cytotoxic effect at either pH, even when treating with concentrations up to 
10 µM (construct concentration is presented as concentration of WT pHLIP).  
 A proliferation assay was employed to evaluate the ability of pHLIPs to deliver 
the amanitin toxin, a relatively cell-impermeable, polar cargo molecule (35, 36). For 
amanitin to induce cytotoxicity it must be translocated across the cell membrane, be 
released from its peptide carrier, and reach its target in the nucleus (RNA polymerase 
II). Amanitin was conjugated via a cleavable disulfide link to the inserting, C-termini 
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of the peptides. The translocation capabilities of the pHLIP-amanitin conjugates were 
measured as the inhibition of proliferation of HeLa cells due to treatment with 
increasing concentrations (up to 2 µM) of pHLIP-amanitin at either physiological pH 
(pH 7.4) or low pH (pH 6.0) for two hours, followed by removal of the constructs, 
transfer of cells to normal cell culture media, and assessment of cell death at 48 hours. 
 Each of the conjugates demonstrated pH-dependent cytotoxicity (Figure S2). 
The calculated EC20, EC50, and EC80 at physiological and low pH are shown in Table 
1. At low pH, the most potent constructs were the pHLIP bundles, which exhibited the 
highest cooperativity of insertion into the membrane. The least toxic at normal pH 
among all constructs was Var3. Figure 2b lists the therapeutic indexes (TI), defined as 
the ratio of EC50 at pH 7.4 to EC50 at pH 6.0 for each case. A TI of about 9 was 
obtained for WT/Gla and Var3, and the TI was around 5.5 for PEG-2WT, Var3/Gla 
and ATRAM. It is also desirable to have high potency, which is defined as the 
difference between cell viability at low and physiological pHs at different 
concentrations of the construct (Figure 3). All constructs had high potency (60-70%) 
at particular concentrations; however, just a few constructs, namely Var3, Var3/Gla, 
and WT/Gla, had a high, stable potency over a wide range of concentrations. pHLIP 
bundles displayed the highest potency at the lowest concentrations (0.1-0.2 µM). The 
potency of ATRAM peaked at concentrations around 0.5 µM and declined sharply at 
higher concentrations; this decline is most likely associated with the increased 
hydrophobicity of ATRAM, which results in a high affinity to the cell membrane at 
normal and high pH and promotes the shift in equilibrium toward the membrane-
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inserted form that is associated with the translocation of cargo across the cell 
membrane. 
 
Tumor targeting. To evaluate the tumor targeting and biodistribution characteristics 
of the pHLIP variants, we conjugated the fluorescent dye Alexa Fluor 546 (AF546) to 
the non-inserting, N-termini of seven of the peptides. Our previous data indicate 
excellent tumor targeting by AF546-pHLIPs (9, 27). In the case of pHLIP bundles, 
AF546 was conjugated to the inserting, C-termini of the PEG-2WT and PEG-4WT 
pHLIPs, as the N-termini were occupied by PEG polymers. A well-established mouse 
model, using implanted cells of acidic 4T1 murine breast tumors, was used in the 
study; this model is targeted well by pHLIPs (9, 27). Following the development of 
breast tumors in the mouse flank, each fluorescent construct was introduced by a 
single tail vein injection. Animals were euthanized four hours after the injection of the 
fluorescent conjugates, and the tumor and major organs (kidney, liver, lungs, spleen, 
and muscle) were collected and imaged. We selected the four-hour post-injection time 
point based on previous pharmacokinetics data which show that the highest tumor 
targeting of pHLIPs is observed four hours after the injection of construct (9, 27). The 
mean values of the surface fluorescence intensity of tumors, muscle, and organs are 
given in Table S4. The normalized tumor fluorescence intensity (normalized by tumor 
uptake of AF546-WT) for all constructs is shown in Figure 4a. The highest tumor 
targeting was observed for the Var3 construct, as well as for Var3/Gla and ATRAM. 
The tumor uptakes of the WT and Var3/GLL constructs were significantly reduced, by 
1.6- and 2.6-fold, respectively, compared to the uptake of Var3. The uptakes of 
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WT/Gla, WT/Gla/Aad, and the pHLIP bundles were reduced even further compared to 
the uptake of the WT construct. It is possible that the decreased tumor targeting 
observed in the PEG-pHLIP bundles might be attributed to the fact that the AF546 dye 
was conjugated to the C-terminus, which is translocated into the cytosol. At the same 
time, the tumor-to-muscle ratio of the WT-like group was in the range of 5.4-7.5. The 
highest tumor-to-muscle ratios were observed for Var3 (T/M=8.9) and PEG-2WT 
(T/M=7.5), and the lowest ratio was observed in Var3/GLL (T/M=4.0) (Figure 4b and 
Table S5). Among all constructs, only Var3/GLL demonstrated a tumor-to-kidney 
ratio less than 1 (Figure 4c and Table S5). The highest tumor-to-liver ratio was found 
in Var3 and Var3/Gla (Figure 4d and Table S5). 
 Because PEG-2WT-AF546 and PEG-4WT-AF546 are several times larger 
than the other pHLIP variants, we hypothesized that they might have slower 
pharmacokinetics. Therefore, we also performed imaging at the 24-hour post-injection 
time point for the two PEG-pHLIP conjugates; however, we did not observe any 
significant signal increase in tumors at 24 hours post-injection compared to 4 hours 
post-injection (Table S4). 
 
Discussion 
In order to advance cancer therapy using a range of agents with different properties, 
we have developed new pHIP variants and pHLIP bundles, and compared their 
performance to the performance of recently introduced variants with non-standard 
amino acids (Gla and Aad) and the hydrophobic glycine-leucine-leucine (GLL) motif. 
Our goal was to correlate the biophysical properties of the membrane interactions of 
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different pHLIPs, including physiological concentrations with free calcium and 
magnesium ions, to the ability of these pHLIPs to move polar cargo across the cell 
membrane and to target acidic tumors.  
 The insertion pK and cooperativity parameters of the steady-state, pH-
dependent transition from State II at pH 8 to State III at pH <5 can be taken as 
predictors of the performance of a pHLIP for drug delivery and tumor targeting (17, 
28, 29). While pK is a rather stable fitting parameter, the cooperativity parameter (Hill 
coefficient) might vary over a wide range resulting from different fittings which are 
within the level of accuracy of the experimental measurements. Moreover, if different 
binding affinities are assumed, the Hill model loses validity. In general, highly 
cooperative transitions are hard to measure in biological systems with noise, especially 
when examining relatively short peptides like those that comprise the class of pHLIP 
peptides (28). Only if the biological system is approximated to be infinite can a phase 
transition occur (37). Moreover, transition parameters for different peptides can only 
be truly compared when both peptides have precisely the same starting and ending 
states; although this condition is met for the membrane-inserted state (State III) of the 
peptides, which appears very similar among pHLIP variants, the condition that the 
initial state (State II) of the peptides be identical is not met. As hydrophobicity varies 
widely among peptides of the pHLIP family due to the difference in numbers of 
protonatable, polar, and hydrophobic residues and their location within the peptide 
sequences, the characteristics of the peptide population in the initial state of the 
transition also varies as these peptides position themselves at different interaction 
levels with the hydrophobic/hydrophilic boundary region of a bilayer. 
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 The population percentages of inserted peptide presented in Table S6 were 
calculated from the pH-dependent transitions of pHLIP variants. The numbers 
represent the percentage of membrane-inserted peptides at varying pH assuming that, 
at the beginning of the transition (State II) (i.e., at physiological pH and higher), the 
population of inserted peptides is close to zero. In reality, close consideration of the 
interaction between a pHLIP variant and the membrane at pH 8, in conditions more 
alkaline than physiological conditions where the inserted peptide population should be 
even less than at physiological conditions, indicates that the most hydrophobic 
sequences, such as ATRAM and Var3/GLL, and bundled pHLIPs with multiple 
binding sites within a single construct, exhibit a significant inserted peptide 
population, as shown by the loss of pH-dependent differences in the translocation of 
the polar, cell-impermeable cargo amanitin with an increase in construct concentration 
(i.e., a decrease in potency at higher concentrations). Due to patient variability, it is 
highly desirable that potential therapeutic pHLIP constructs be able to discriminate 
between healthy and tumor tissue over a wide concentration range, meaning that a 
constant potency is necessary to avoid targeting normal tissue and the resulting 
significant side effects, which suggests that these variants (i.e., ATRAM, Var3/GLL, 
and bundled pHLIPs) may not be well suited for clinical development using agents 
that require tight targeting. 
 In addition to the steady-state experiments, it is important to probe tumor 
targeting and to examine the biodistribution of the constructs when injected into the 
high-flowrate blood stream, since targeted delivery is always diminished by clearance 
via the blood. The best tumor targeting was shown by faster-inserting pHLIP 
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constructs; thus, in the design of new pHLIP variants, the biophysical kinetics 
parameters need to be considered in addition to the more traditionally prioritized 
steady-state properties. These kinetics parameters might be especially critical for the 
delivery and translocation of a cargo across a membrane, since we have shown that 
charges and the presence of cargo at the inserting end of a pHLIP can slow the process 
of insertion (24). Different cargoes linked to a pHLIP alter biodistribution and tumor 
targeting (27). Less polar pHLIP variants conjugated with hydrophobic cargoes might 
have a higher tendency toward targeting normal tissue and hepatic clearance. On the 
other hand, the size of links in pHLIP bundles could be used to tune biodistribution 
and redirect clearance from renal to hepatic. 
 Among the pHLIP variants we investigated, Var3 demonstrated excellent 
performance in vitro (displaying the most stable potency over a wide range of 
concentrations) and in vivo, displaying high tumor targeting. Variants containing the 
Gla residue, especially the WT/Gla construct, showed an increase in the cooperativity 
of the membrane insertion transition as previously reported (28), and showed an 
improved therapeutic index; however, the tumor targeting of WT/Gla was lower 
compared to the tumor targeting of WT. 
 γ-carboxyglutamic acid is not naturally encoded in the human genome, but is 
introduced into proteins through the post-translational carboxylation of glutamic acid, 
resulting in an amino acid with two carboxyl groups. Many proteins are known to have 
Gla-rich domains, including several coagulation factors which, by coordinating 
calcium ions, are induced to change conformation and increase their hydrophobicity 
and affinity to the cell membrane bilayer (38). Calcium complex formation by a 
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pHLIP increases the hydrophobicity of the peptide and alters the interaction between 
peptide and membrane; this fact, along with the fact that the cost of synthesizing a 
Gla-containing peptide is very high (Gla is one of the most expensive amino acids) 
might somewhat reduce enthusiasm for using the Gla residue, although if there were 
sufficient advantages in a specific case the cost might be justified. While considering 
peptide synthesis, it is worthwhile to note that very hydrophobic pHLIP sequences 
(like ATRAM), especially when coupled with even moderately hydrophobic cargoes, 
might be challenging to produce in the large quantities needed for clinical translation.  
 There is no single recipe for the best pHLIP: the peptide will need to be 
tailored to each specific medical application. For example, kidney clearance might be 
preferred to liver clearance for PET-pHLIP imaging constructs (13). High tumor-to-
normal tissue fluorescence intensity ratios will be the key in fluorescence-guided 
surgery applications (11). Delivery of highly toxic molecules, such as amanitin, would 
require minimal off-targeting, thus high potency and therapeutic index will be critical. 
However, for the delivery of polar peptide nucleic acids (PNAs) or other highly 
specific inhibitors of particular pathways in cancer cells, neither of which are 
associated with toxicity in normal cells, the requirement to reduce off-targeting might 
be much lower and the emphasis would be shifted toward the efficiency of delivery, 
the goal being to translocate as much cargo as possible (18, 39). pHLIP bundles might 
yield excellent results in these types of applications, supported by the observation that 
PEG-4WT was the most efficient at delivering the polar molecule amanitin to the 
intracellular space. We suspect that bundling multiple Var3 pHLIPs, in the same 
fashion that we linked two or four WT pHLIPs, might be even more advantageous. 
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Var3 demonstrates membrane insertion rates orders of magnitude faster than the 
insertion rates of WT; with the knowledge that faster insertion rates observed in 
biophysical experiments correlates to better tumor targeting in vivo, it stands to reason 
that potential PEG-Var3 constructs might demonstrate better tumor targeting still. 
 In drug delivery applications, pHLIP peptides are best designed for the 
delivery of polar, cell-impermeable molecules (14, 35, 40, 41). The intracellular 
delivery of a polar cargo could be further tuned by altering the link connecting the 
cargo to pHLIP and/or by attaching modulator molecules to the inserting end of the 
peptide (14, 15, 18, 35). Additionally, pHLIP could be used for the targeted delivery 
of cell-permeable, drug-like molecules since it can significantly increase the time of 
retention in blood, positively alter the biodistribution of drugs that typically rely on 
passive diffusion, and enhance tumor targeting, all of which would lead to an increase 
in therapeutic index (16). More polar pHLIP variants are expected to be better suited 
to applications involving the intracellular delivery of cell-permeable cargoes. 
 We have now established a set of properties for a number of pHLIPs, which 
can be selected as starting points for clinical development in different circumstances. 
This body of work, along with the prior studies, opens pathways for targeted delivery 
using a range of imaging and therapeutic agents in the fight against cancer. 
 
Materials and Methods 
The details of experimental protocols can be found in Supplementary Materials and 
Methods. 
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TABLES 
Table 1. The midpoint (pK), cooperativity (n), and time (t) parameters characterizing 
the pH-dependent transition of pHLIP variants in the presence of POPC liposomes are 
presented. EC20, EC50, and EC80 values were calculated for each pHLIP-amanitin 
construct at physiological and low pH by analyzing the pH- and concentration-
dependent cell viability data (Figure S2). 
 
  
Peptide pK n t (s) 
EC20 (µM) EC50 (µM) EC80 (µM) 
pH 7.4 pH 6.0 pH 7.4 pH 6.0 pH 7.4 pH 6.0 
WT 6.5 1.8 36.8 1.95 1.22 1.37 0.56 0.96 0.26 
WT/Gla 6.2 1.5 37.5 6.20 0.93 2.73 0.30 1.20 0.10 
WT/Gla/Aad 6.6 1.4 34.8 3.01 0.66 1.39 0.37 0.64 0.21 
PEG-2WT 6.6 1.8 18.8 1.98 0.54 1.03 0.19 0.53 0.07 
PEG-4WT 6.6 2.2 13.1 0.473 0.19 0.33 0.11 0.23 0.06 
Var3 5.7 0.9 0.9 10.63 1.30 3.95 0.43 1.47 0.14 
Var3/Gla 6.3 0.7 0.7 5.12 1.34 2.76 0.50 1.48 0.19 
Var3/GLL 6.6 0.4 0.1 1.75 0.47 0.91 0.23 0.47 0.11 
ATRAM 6.4 0.9 0.1 2.06 0.40 1.23 0.22 0.74 0.12 
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FIGURES 
Figure 1. Schematic organization of pHLIP bundles: (a) PEG-2WT with 2 kDa 2-arm 
PEG and two WT pHLIPs, and (b) PEG-4WT with 2 kDa 4-arm PEG and four WT 
pHLIPs. Transitions between the three states of PEG-2WT and PEG-4WT in 
phosphate buffer at pH 8 (State I), in the presence of POPC liposomes at pH 8 (State 
II), and in the presence of liposomes at pH 4 (State III) were monitored by changes of 
tryptophan fluorescence (c and d), circular dichroism (e and f), and oriented circular 
dichroism (OCD) (g and h) signals. Normalized pH-dependent steady-state transitions 
from State II to State III were examined by analyzing the shift in position of 
fluorescence spectrum maximum of PEG-2WT (i) and PEG-4WT (j) in the presence 
of physiological concentrations of calcium and magnesium ions. The data were fitted 
using the Henderson-Hasselbalch equation; the fitting curves and 95% confidence 
interval are shown by red and blue lines, respectively. 
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Figure 2. Ellipticity ratios of CD signals at 205 nm to 222 nm are shown for pHLIP 
variants in State I, II, and III (a). The values of ellipticity ratios are given in Table S3. 
The therapeutic index (TI) was calculated for different pHLIP-amanitin constructs as 
the ratio of EC50 at pH 7.4 to EC50 at pH 6.0 (b). 
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Figure 3. pH-dependent potency was defined as the difference between cancer cell 
viability when cells were incubated at pH 7.4 and pH 6.0 at varying concentrations of 
different pHLIP-amanitin constructs. The WT-like group is shown in (a); the Var3-
like group and ATRAM are shown in (b). 
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Figure 4. Normalized tumor fluorescence intensities of the AF546-pHLIP constructs 
are shown; the signals were normalized by the tumor intensity of AF546-WT (a). 
Tumor-to-muscle (T/M) (b), tumor-to-kidney (T/K) (c), and tumor-to-liver (T/L) (d) 
fluorescence intensity ratios are shown. Statistically significant differences were 
determined by two-tailed unpaired Student’s t-test, where * denotes p ≤0.05 and ** 
denotes p ≤0.005. 
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Supplementary Materials and Methods 
pHLIP characterization and pHLIP bundle synthesis. All peptides were purchased 
from CS Bio Co. Peptides were characterized by reversed phase high-performance 
liquid chromatography (RP-HPLC) using Zorbax SB-C18 and Zorbax SB-C8, 4.6 × 
250 mm, 5 μm columns (Agilent Technology). For biophysical measurements, PEG-
2WT and PEG-4WT were made by conjugating either 2 kDa bifunctional maleimide-
PEG-maleimide or 2 kDa 4-arm PEG-maleimide (Creative PEGWorks) to Cys-WT 
via an N-terminal cysteine residue. Purification of the PEG-pHLIP constructs was 
conducted using RP-HPLC. Peptide concentration was calculated by absorbance at 
280 nm, where, for WT, WT/Gla, and WT/Gla/Aad, ε280 = 13,940 M
-1
 cm
-1
; for Var3, 
Var3/Gla, and Var3/GLL, ε280 = 12,660 M
-1
 cm
-1
; and for ATRAM, ε280 = 5,690 M
-1
 
cm
-1
. PEG construct concentration was presented in terms of peptide concentration, 
not molecular concentration. 
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Liposome preparation. Small unilamellar vesicles were used as model membranes 
and were prepared by extrusion. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC; Avanti Polar Lipids) was dissolved in chloroform at a concentration of 12.5 
mg/mL, then desolvated by rotary evaporation for two hours under vacuum. The 
resulting POPC film was rehydrated in 10 mM phosphate buffer at pH 8, either with 
additional calcium and magnesium ions (1.25 mM calcium and 0.65 mM magnesium), 
or without additional ions, vortexed, and extruded fifteen times through a membrane 
with a pore size of 50 nm. 
 
Steady-state fluorescence measurements. Steady-state fluorescence spectra were 
measured using a PC1 spectrofluorometer (ISS) with temperature control set to 25.0 
°C. The tryptophan fluorescence was excited using an excitation wavelength of 295 
nm. Excitation and emission slits were set to 8 nm, and excitation and emission 
polarizers were set to 54.7° and 0.0°, respectively. Sample preparation was conducted 
24 hours prior to experiments to allow for State II equilibration. A buffer-only sample 
was used as a baseline for State I, and a buffer-with-POPC-only sample was used as a 
baseline for States II and III. 
 
pH dependence measurements. Measurements of pH dependence were taken with 
the PC1 spectrofluorometer by using the shift in the position of maximum of peptide 
fluorescence as an indication of changes of the peptide environment at varying pH. All 
pH dependence measurements were conducted using blood physiological 
concentrations of free calcium and magnesium ions (1.25 and 0.65 mM, respectively). 
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After the addition of hydrochloric acid, the pH of solutions containing 5 µM peptide 
and 1 mM POPC were measured using an Orion PerHecT ROSS Combination pH 
Micro Electrode and an Orion Dual Star pH and ISE Benchtop Meter (Thermo Fisher 
Scientific) before and after spectrum measurement to ensure equilibration. The 
tryptophan fluorescence spectrum at each pH was recorded, and the spectra were 
analyzed using the Protein Fluorescence and Structural Toolkit (PFAST) (42) to 
determine the positions of spectral maxima (𝜆max). The position of 𝜆max was plotted 
as a function of pH and normalized, such that 𝜆max
initial − position of spectral maximum 
in State II was set to 1 and 𝜆max
final − position of spectral maximum in State III, was set 
to 0. The normalized pH-dependence was fit with the Henderson-Hasselbach equation 
(using OriginLab software) to determine the cooperativity (𝑛) and transition mid-point 
(p𝐾) of transition of the peptide population from State II to State III: 
 
 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝐻 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑒 =
1
1+10𝑛(pH−p𝐾)
     (1) 
 
Steady-state circular dichroism and oriented CD measurements. Steady-state CD 
was measured using an MOS-450 spectrometer (Bio-Logic Science Instruments) in the 
range of 190 to 260 nm with a step size of 1 nm, and with temperature control set to 
25.0 °C. Samples were prepared 24 hours prior to experiments to allow for State II 
equilibration. A buffer-only sample was used as baseline for State I, and a buffer-with-
POPC-only sample was used as baseline for States II and III. 
 OCD was measured using supported planar POPC bilayers prepared using a 
Langmuir-Blodgett system (KSV Nima). Fourteen quartz slides with 0.2 mm spacers 
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were used; after sonicating the slides in 5% cuvette cleaner (Contrad 70; Decon Labs) 
in deionized water (≥18.2 MΩ cm at 25 °C; Milli-Q Type 1 Ultrapure Water System, 
EMD Millipore) for fifteen minutes and rinsing with deionized water, the slides were 
immersed and sonicated for ten minutes in 2-propanol, sonicated again for ten minutes 
in acetone, sonicated a final time in 2-propanol for ten minutes, and rinsed thoroughly 
with deionized water. Lastly, the slides were immersed in a 3:1 solution of sulfuric 
acid to hydrogen peroxide for five minutes and rinsed three times in deionized water. 
The slides were stored in deionized water until they were used. POPC bilayers were 
deposited on the fourteen slides using a Langmuir-Blodgett minitrough: a 2.5 mg/mL 
solution of POPC in chloroform was spread on the subphase (deionized water) and the 
chloroform was allowed to evaporate for fifteen minutes, after which the POPC 
monolayer was compressed to 32 mN/m. A lipid monolayer was deposited on the 
slides by retrieving them from the subphase, after which a solution of 10 µM peptide 
and 500 µM of 50 nm POPC liposomes at pH 4 was added to the slides, resulting in 
the creation of the supported bilayer by fusion between the monolayer on the slides 
and the peptide-laden lipid vesicles. After incubation for six hours at 100% humidity, 
the slides were rinsed with buffer solution to remove excess liposomes, and the spaces 
between the cuvettes were filled with buffer at pH 4. Measurements were taken at 
three points during the experiment: immediately after the addition of the peptide/lipid 
solution (0 h), after the slides were rinsed to remove excess liposomes following the 
six-hour incubation time (6 h), and after an additional twelve-hour incubation time and 
rinse with buffer (18 h); these measurements were recorded on the MOS-450 
spectrometer with sampling times of two seconds at each wavelength. Control 
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measurements were conducted using a peptide solution between slides without 
supported bilayers and in the presence of POPC liposomes. 
 
Kinetics measurements. Stopped-flow fluorescence measurements were made using 
an SFM-300 mixing system (Bio-Logic Science Instruments) in conjunction with the 
MOS-450 spectrometer. All solutions were degassed for fifteen minutes prior to 
loading into the stopped-flow system. pHLIP variants were incubated with POPC for 
24 hours prior to the experiment to reach State II equilibrium, and insertion was 
induced by mixing equal volumes of pHLIP/POPC solutions with hydrochloric acid 
diluted to ensure a pH drop from pH 8 to pH 4. Kinetics data were fit by one-, two-, 
three-, or four-state exponential models in OriginLab. 
 
Amanitin pHLIP conjugates. α-amanitin (Sigma-Aldrich) was conjugated to 
succinimidyl 3-(2-piridyldithio)propionate) (SPDP; Thermo Fisher Scientific), 
followed by purification and conjugation of the SPDP-amanitin to the C-terminal 
cysteine residues of pHLIP peptides. For synthesis of PEG-2WT-amanitin and PEG-
4WT-amanitin, Lys-WT-Cys with N-terminal lysine and C-terminal cysteine residues 
was used, and the Lys-WT-SPDP-amanitin was conjugated to dibenzocyclooctyne-
sulfo-N-hydroxysuccinimidyl ester (DBCO-NHS ester; Sigma-Aldrich), resulting in 
DBCO-WT-SPDP-amanitin. Finally, 2-arm or 4-arm PEG-azide (Creative 
PEGWorks) was conjugated to DBCO-WT-SPDP-amanitin, resulting in PEG-DBCO-
WT-SPDP-amanitin, with a cleavable disulfide bond present in SPDP, between the 
peptide and amanitin cargo. Construct concentration was calculated by absorbance at 
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310 nm, where, for α-amanitin, ε310 = 13,000 M
-1
 cm
-1
. Construct concentration was 
presented in terms of peptide/amanitin concentration. Purification was conducted 
using RP-HPLC. Zorbax SB-C18 columns (9.4 × 250 mm, 5 µm; Agilent 
Technologies) were used for all peptide-amanitin conjugates other than ATRAM-
amanitin, PEG-2WT-amanitin, and PEG-4WT-amanitin, for which Zorbax SB-C8 
columns (9.4 × 250 mm, 5 µm; Agilent Technologies) were used. 
 
Cell proliferation assay. Human cervix adenocarcinoma cells (HeLa; American Type 
Culture Collection) were authenticated, stored according to the instructions of the 
supplier, and used within three months of frozen aliquot resuscitation. Cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) at pH 7.4 
with 4.5 g/L D-glucose, supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Sigma-Aldrich) and 10 µg/mL ciprofloxacin (Sigma-Aldrich), in a humidified 
atmosphere of 5% CO2 and 95% air at 37 °C. The pH 6.0 medium was prepared by 
mixing 13.3 g of dry DMEM in 1 L of deionized water. HeLa cells were loaded in the 
wells of 96-well plates (5,000 cells/well) and incubated overnight. The standard 
growth medium was replaced with medium without FBS, at pH 6.0 or 7.4, containing 
increasing amounts of pHLIP-amanitin conjugates (from 0 to 2.0 µM). Treatment with 
amanitin alone for two hours and at concentrations up to 2 µM does not induce cell 
death (35). After two-hour incubation with the pHLIP-amanitin conjugates, the 
constructs were removed and replaced with standard growth medium. Cell viability 
was assessed after 48 hours using the CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega); the colorimetric reagent was added to cells for one 
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hour, followed by absorption measurement at 490 nm. All samples were prepared in 
triplicate, and each experiment was repeated between 3 and 6 times. All obtained cell 
proliferation data were normalized by corresponding controls (non-treated cells). 
There was no difference in the viability of cells incubated with media, without 
construct, at pH 7.4 and pH 6.0; therefore, the role of pH was excluded from the 
consideration. Normalized cell viability data obtained in different experiments were 
averaged and presented in terms of the logarithm of dose of pHLIP-amanitin 
constructs. The dose-response function was used for fitting the obtained data (Figure 
S2) (OriginLab): 
 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝐴𝑏 +
𝐴𝑡−𝐴𝑏
1+10𝑝(log 𝑥0−𝑥)
       (2) 
 
where 𝐴𝑏 and 𝐴𝑡 are the bottom and the top asymptotes, respectively. The top 
asymptote was set as constant (100%) while for the bottom asymptote we allowed 
small variations in the range of 0 to 10%. 𝑝 is the slope (cooperativity parameter) and 
log 𝑥0 is the center of the transition (i.e., the concentration for half response) which is 
used to calculate the EC20, EC50, EC80 values: 
 
𝐸𝐶20 = 10
(log 𝑥0+
log 0.25
𝑝⁄ )        (3) 
 
𝐸𝐶50 = 10
log 𝑥0         (4) 
 
𝐸𝐶80 = 10
(log 𝑥0+
log 4
𝑝⁄ )        (5) 
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Therapeutic index (TI) was calculated according to the equation: 
 
𝑇𝐼 =
𝐸𝐶50
p𝐻 7.4
𝐸𝐶50
p𝐻 6.0          (6) 
  
Additionally, the cytotoxicity of the PEG-2WT and PEG-4WT constructs without 
amanitin was tested: these experiments demonstrated no cytotoxicity at physiological 
or low pH at treatment concentrations up to 10 µM. 
 
Fluorescent pHLIP conjugates. Alexa Fluor 546 (AF546) C5 maleimide (Thermo 
Fisher Scientific) was conjugated to the N-terminal cysteine residues of WT, Var3, 
Var3/Gla, and ATRAM. AF546 NHS Ester (Thermo Fisher Scientific) was conjugated 
to the N-terminal lysine residues of WT/Gla, WT/Gla/Aad, and Var3/GLL. For PEG-
2WT and PEG-4WT, Cys-WT-Lys, with N-terminal cysteine and C-terminal lysine 
residues, was used, and was first conjugated to 2-arm maleimide-PEG-maleimide or 4-
arm PEG-maleimide resulting in PEG-WT-Lys. Then, AF546 NHS Ester was 
conjugated to the C-terminal lysine residue, resulting in 2-arm and 4-arm PEG-pHLIP 
constructs with C-terminal AF546 fluorophores. Construct concentration was 
calculated by absorbance at 554 nm, where, for AF546, ε554 = 93,000 M
-1
 cm
-1
. 
Construct concentration was presented in terms of AF546/peptide concentration, not 
molecular concentration. Purification was conducted using RP-HPLC for all peptides 
other than PEG-4WT-AF546, which was purified via Amicon Ultra MWCO 10 kDa 
centrifugal filter (Sigma-Aldrich). Zorbax SB-C18 columns (9.4 × 250 mm, 5 µm; 
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Agilent Technologies) were used for all AF546-peptide conjugates except AF546-
ATRAM and PEG-2WT-AF546, for which Zorbax SB-C8 columns (9.4 × 250 mm, 5 
µm; Agilent Technologies) were used. 
 
Ex vivo imaging. All animal studies were conducted according to the animal protocol 
AN04-12-011 approved by the Institutional Animal Care and Use Committee at the 
University of Rhode Island, in compliance with the principles and procedures outlined 
by the National Institutes of Health for the care and use of animals. Mouse mammary 
cells (4T1; American Type Culture Collection) were subcutaneously implanted in the 
right flank (8 × 10
5
 cells/0.1 mL/flank) of adult female BALB/cAnNHsd mice 
(Envigo). When tumors reached approximately 5-6 mm in diameter, single tail vein 
injections of 100 µL, 40 µM fluorophore-pHLIP solutions in PBS were performed. 
Mice were euthanized 4 or 24 hours after injection, and necropsy was immediately 
performed. Tumors and major organs were cut in half and imaged using an FX Kodak 
in-vivo image station connected to an Andor CCD camera. Mean surface fluorescence 
intensity of tumor, tissue and organs was obtained via analysis of fluorescence images 
in ImageJ (NIH) (43). The corresponding autofluorescence signal was subtracted to 
obtain the net fluorescence intensities used in the study. Autofluorescence was 
calculated after imaging tumors, tissue, and organs collected from mice with no 
injection of fluorescent pHLIP constructs. 
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SUPPLEMENTARY TABLES 
Table S1. List of pHLIP sequences used in the study. 
 
Peptide Sequence 
Cys-WT ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT 
WT-Cys AEQNPIYWARYADWLFTTPLLLLDLALLVDADEGCT 
Lys-WT-Cys Ac-AKEQNPIYWARYADWLFTTPLLLLDLALLVDADECT 
Lys-WT/Gla-Cys Ac-AKEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADECT 
Lys-WT/Gla/Aad-Cys Ac-AKEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADECT 
Cys-Var3 ACDDQNPWRAYLDLLFPTDTLLLDLLWA 
Var3-Cys ADDQNPWRAYLDLLFPTDTLLLDLLWCA 
Cys-Var3/Gla ACDDQNPWRAYLGlaLLFPTDTLLLDLLWG 
Var3/Gla-Cys ADDQNPWRAYLGlaLLFPTDTLLLDLLWCG 
Lys-Var3/GLL-Cys Ac-GKEEQNPWLGAYLDLLFPLELLGLLELGLWCG 
Cys-ATRAM ACGLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGN 
ATRAM-Cys GLAGLAGLLGLEGLLGLPLGLLEGLWLGLELEGNCA 
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Table S2. Molecular weights (MW) of peptides, and retention times and 
corresponding percentages of acetonitrile at elution for 30 min method of 25-80% 
gradient of acetonitrile/0.05% TFA in water/0.05% TFA used in C18 and C8 columns. 
†
Peptide eluted during washing with acetonitrile, after the completion of the gradient. 
 
Peptide MW (Da) 
Zorbax SB-C18  
(4.6 × 250 mm, 5 µm) 
Zorbax SB-C8  
(4.6 × 250 mm, 5 µm) 
Retention 
Time (min) 
% Acetonitrile 
Retention 
Time (min) 
% Acetonitrile 
Cys-WT 4111.7 21.6 64.6% 20.6 62.8% 
Lys-WT-Cys 4224.9 21.6 64.6% 20.4 62.4% 
Lys-WT/Gla-Cys 4283.1 22.3 65.9% 21.2 63.9% 
Lys-WT/Gla/Aad-Cys 4310.9 22.8 66.8% 21.7 64.8% 
Cys-Var3 3292.8 19.7 61.1% 19.6 60.9% 
Cys-Var3/Gla 3333.8 19.9 61.5% 19.7 61.1% 
Lys-Var3/GLL-Cys 3643.2 28.0 76.2% 26.0 72.7% 
Cys-ATRAM 3516.2 30.6
† 93.0% 27.2 74.9% 
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Table S3. Positions of maxima of tryptophan fluorescence spectra (λmax) and ratios of 
ellipticity at 205 nm to 222 nm of pHLIP constructs in States I, II, and III are given. 
 
Construct 
λmax (nm) Ellipticity at 205/222 nm 
State I State II State III State I State II State III 
WT 351.6 347.4 340.0 1.61 2.16 0.68 
WT/Gla 348.2 347.1 338.2 2.02 1.60 0.70 
WT/Gla/Aad 347.5 346.7 338.3 1.60 1.31 0.68 
PEG-2WT 341.8 341.2 336.6 1.12 1.48 0.71 
PEG-4WT 344.0 343.4 338.9 1.18 1.07 0.71 
Var3 350.2 346.8 339.9 2.35 1.55 0.71 
Var3/Gla 351.4 345.7 339.2 2.72 1.76 0.85 
Var3/GLL 349.3 343.3 341.2 2.21 1.32 0.84 
ATRAM 345.5 341.4 333.0 2.45 1.44 0.85 
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Table S4. Fluorescence intensity obtained by ex vivo imaging of tumor, tissue, and 
organs 4 hours after a single IV administration of the Alexa Fluor 546-pHLIP 
constructs (data obtained at 24 hours post-injection are shown for PEG-2WT and 
PEG-4WT). Values of tissue autofluorescence are provided in the last row. Sample 
size (n) is given in the last column for each construct. 
 
Construct 
Total Fluorescence Intensity in tumor, muscle and organs (a.u.) 
Tumor Muscle Kidney Liver Lungs Spleen n 
WT 2335.7 ± 447.1 726.8 ± 58.5 988.5 ± 91.0 998.7 ± 142.0 545.8 ± 32.6 447.0 ± 31.7 5 
WT/Gla 1372.1 ± 331.7 591.2 ± 73.2 880.2 ± 126.5 1102.1 ± 239.6 456.2 ± 68.6 387.9 ± 63.3 13 
WT/Gla/Aad 1336.6 ± 304.5 559.6 ± 53.5 726.6 ± 149.9 1156.4 ± 120.8 448.5 ± 79.9 374.1 ± 45.0 13 
PEG-2WT 1443.4 ± 178.5 545.3 ± 42.2 602.7 ± 79.2 1267.1 ± 146.2 462.0 ± 28.5 450.7 ± 17.3 5 
PEG-4WT 912.8 ± 159.5 495.5 ± 23.0 523.4 ± 52.5 1209.7 ± 100.7 431.0 ± 54.9 403.7 ± 30.0 7 
Var3 3474.3 ± 924.2 760.7 ± 68.3 1263.9 ± 136.5 904.8 ± 93.4 564.3 ± 130.1 335.6 ± 45.0 7 
Var3/Gla 2948.9 ± 540.6 889.3 ± 144.7 1390.0 ± 247.5 702.9 ± 140.9 784.5 ± 248.7 379.2 ± 47.8 5 
Var3/GLL 1577.9 ± 364.2 694.2 ± 27.5 1690.8 ± 431.8 1194.3 ± 147.1 520.2 ± 18.6 442.8 ± 37.4 5 
ATRAM 3039.5 ± 620.9 813.3 ± 105.4 1009.8 ± 183.9 1073.2 ± 146.3 716.6 ± 109.0 421.3 ± 35.3 9 
PEG-2WT (24 h) 894.9 ± 151.8 486.3 ± 19.8 525.1 ± 37.6 753.6 ± 54.0 547.2 ± 64.8 346.3 ± 11.0 5 
PEG-4WT (24 h) 663.5 ± 121.1 440.1 ± 7.7 464.2 ± 35.1 726.7 ± 69.6 482.8 ± 48.5 331.8 ± 4.4 5 
Autofluorescence 426.9 ± 15.7 402.7 ± 11.5 325.6 ± 30.8 354.7 ± 28.3 392.7 ± 32.7 296.1 ± 23.2 12 
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Table S5. Tumor-to-muscle (T/M), tumor-to-kidney (T/K), and tumor-to-liver (T/L) 
ratios presented in Figures 4b, 4c, and 4d, respectively. 
 
Construct T/M T/K T/L 
WT 5.87 ± 0.64 2.95 ± 0.95 3.03 ± 0.76 
WT/Gla 5.39 ± 1.65 1.77 ± 0.68 1.40 ± 0.76 
WT/Gla/Aad 6.54 ± 3.15 2.59 ± 1.33 1.14 ± 0.37 
PEG-2WT 7.48 ± 1.86 3.80 ± 0.77 1.13 ± 0.19 
PEG-4WT 5.34 ± 1.53 2.55 ± 0.78 0.57 ± 0.17 
Var3 8.86 ± 3.61 3.38 ± 1.34 5.62 ± 1.90 
Var3/Gla 5.30 ± 0.89 2.46 ± 0.64 8.29 ± 4.19 
Var3/GLL 4.03 ± 1.54 0.87 ± 0.23 1.42 ± 0.55 
ATRAM 6.56 ± 1.55 3.96 ± 1.05 3.72 ± 1.01 
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Table S6. The membrane-inserted populations of different pHLIP variants were 
calculated using the pH dependence parameters pK and n (Table 1). 
 
pH WT WT/Gla WT/Gla/Aad PEG-2WT PEG-4WT Var3 Var3/Gla Var3/GLL ATRAM 
7.4 2% 2% 7% 4% 2% 3% 15% 32% 11% 
7.2 5% 3% 13% 8% 5% 4% 19% 37% 16% 
7.0 11% 6% 22% 16% 12% 6% 24% 41% 22% 
6.8 22% 11% 34% 30% 27% 9% 31% 45% 30% 
6.5 50% 26% 58% 60% 62% 16% 42% 52% 45% 
6.2 78% 50% 78% 84% 88% 26% 54% 59% 60% 
6.0 89% 67% 87% 92% 95% 35% 62% 63% 70% 
  
  
 
 
203 
 
Fig. S1. Three-state tryptophan fluorescence (A and D), circular dichroism (B and E), 
and pH dependence plots (C and F) are shown for Var3/Gla (A-C) and Var3/GLL (D-
F) pHLIP variants. Transitions between the three folding states of Var3/Gla and 
Var3/GLL pHLIP variants in phosphate buffer at pH 8 (State I), in the presence of 
POPC liposomes at pH 8 (State II), and in the presence of liposomes at pH 4 (State III) 
were monitored by changes of tryptophan fluorescence (A and D), and circular 
dichroism (B and E) signals. pH-dependent steady-state transitions from State II to 
State III were examined by analyzing the shift of the position of tryptophan 
fluorescence spectrum maxima of Var3/Gla (C) and Var3/GLL (F) constructs in the 
presence of physiological concentrations of calcium and magnesium ions. The data 
were fitted using the Henderson–Hasselbalch equation; the fitting curves and 95% 
confidence interval are shown by red and blue lines, respectively. 
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Fig. S2. Cell viability data were obtained after treatment of HeLa cells with pHLIP-
amanitin constructs for 2 hours at pH 7.4 and pH 6.0, followed by removal of the 
constructs, transferal of cells to normal cell culture media, and assessment of cell 
death at 48 hours by MTS assay. 
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